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ABSTRACT
Objective: The objective of this study was to assess the prevalence and predictors of use of
hydroxyurea (HU) and its impact on clinical and economic outcomes in pediatric patients with
sickle cell disease (SCD) enrolled in Medicaid.
Methods: A cohort of patients with SCD was identified in 2006 using ICD-9-CM codes from
Medicaid claims from 40 US states. Patients who filled three prescriptions of HU in within 6
months in 2007 were identified as HU users. HU users were then matched with non-users and
the impact of HU use on the presence of crises and economic outcomes including presence of
hospitalizations and emergency department visits were assessed using conditional logistic
regression stratified on matched pairs. Length of stay and medical costs were compared in the
matched sample using generalized linear models. An additional clinical outcome, number of
crises, was evaluated in the unmatched sample of HU users and non-users using conventional
multivariable regression. Estimates obtained using this approach, were then compared with
those obtained by minimizing selection bias using regional variation and physician preferencebased instrumental variables (IVs).
Results: Prevalence of HU use in children with SCD enrolled in Medicaid was found to be
10.72%. Age, gender, race, disease severity, previous office visits, presence of a comprehensive
sickle cell center within the state of residence, and prior opioid use were all found to be
significant predictors of HU use in this population (p<0.0001). HU users had a significantly
greater likelihood of having a hospitalization (OR:2.09; 95% CI:1.28-3.43) and a longer LOS
ii

(β=0.49; 95% CI:0.14-0.84) compared to non-users. Even though the conventional multivariable
model showed that HU users had a significantly greater number of crises compared to non-users
(β=0.93; p<0.0001), analysis using IVs found no statistically significant relationship (β=-2.75;
p=0.2013).
Conclusion: HU use is not very prevalent among children with SCD enrolled in Medicaid.
Based on the identified predictors, it seems that physicians follow guidelines when prescribing
HU in this population. Since this study failed to corroborate the benefit associated with the use
of HU on clinical outcomes and resource utilization, physicians should be wary in prescribing
HU in this population.
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CHAPTER 1
INTRODUCTION

1

This introductory section provides an overview of sickle cell disease (SCD), describes the
epidemiology, disease burden, quality of life, and mortality in SCD, explores management
options for SCD, and also provides an overview of hydroxyurea (HU), a drug used in patients
with SCD. This section concludes with specific aims and significance of this study.
Overview of SCD
SCD is a genetic disorder of the blood characterized by abnormal red blood cells (RBCs).
SCD is primarily caused by mutations in the gene for hemoglobin, the iron-containing oxygencarrier protein in the blood. In normal individuals, RBCs are composed of hemoglobin ‘A’ due
to which they are soft and round. This allows RBCs to easily move through blood vessels.
RBCs of patients with SCD develop abnormal hemoglobin proteins (such as ‘hemoglobin S’,
‘hemoglobin C’, etc.) which make the RBCs ‘sickle’-shaped and cause a decrease in their flexibility

while passing through blood vessels.1 Sickle-shaped RBCs have a tendency to get lodged in
blood vessels resulting in decreased blood flow to limbs and other organs. This causes episodes
of pain commonly termed as vaso-occlusive events or crises (VOEs), and other complications
including episodes of acute chest syndrome (ACS), chronic organ damage, infections, splenic
sequestration, anemia, renal and genitourinary issues, and priapism.1 Individuals of African
descent exhibit the highest likelihood of developing the disease.2 SCD is also common among
patients with lineage in South America, the Caribbean, Central America, Saudi Arabia, India,
and Mediterranean countries such as Turkey, Greece, and Italy.3

2

Types of SCD
People suffer from several different sub-types of SCD depending on the genotype.
Sickle Cell Anemia (HbSS), Sickle-Hemoglobin C Disease (HbSC), Sickle-Beta
Thalassemia (HbS beta Thalassemia) are the most common types of SCD.4
HbSS: People with this form of SCD inherit two genes for abnormal hemoglobin ‘S’,
one from each parent. In this case, the affected individual has most or all of the normal
hemoglobin (HbA) replaced with the sickle hemoglobin (HbS). HbSS is the most
common and usually the most severe form of the disease. Severe and chronic anemia is a
common characteristic for patients with HbSS along with risk of complications such as
VOEs, organ damage, and infections.
HbSC: People who have this form of SCD inherit a gene for abnormal hemoglobin ‘S’
from one parent and a gene for abnormal hemoglobin ‘C’ from the other parent.
Hemoglobin ‘C’ results in the development of RBCs called target cells where there is a
decrease in the mean hemoglobin concentration. Once the sickle hemoglobin ‘S’ is
combined with the target cell, some mild to moderate anemia may occur. People with
this subtype also suffer from some of the complications associated with HbSS, but to a
milder degree. VOEs, organ damage, and high risk for infection may also occur in
patients with HbSC.
HbS beta-Thalassemia: People with this form of SCD inherit a gene for abnormal
hemoglobin ‘S’ from one parent and a gene for beta-thalassemia from the other parent.
There are two types of beta thalassemia: ‘0’ and ‘+’. People with HbS beta 0-thalassemia
usually have a severe form of SCD while those with HbS beta +-thalassemia tend to have
3

a milder form of SCD. This subtype of SCD produces symptoms of moderate anemia
and many of the same complications associated with HbSS, but to a milder degree.
HbSD, HbSE, and HbSO: These are comparatively rarer forms of SCD. People who
have these forms of SCD inherit one gene for abnormal hemoglobin ‘S’ and one gene for
an abnormal type of hemoglobin including ‘D’, ‘E’, or ‘O’. Often, the signs and
complications of these subtypes are similar to those of a person with the HbSS subtype.
Sickle cell trait: In addition to the subtypes described above, patients might suffer from
sickle cell trait. Patients with sickle cell trait are carriers of the disease, but do not have
SCD. Individuals with sickle cell trait carry the gene for defective hemoglobin (HbS) but
also have some normal hemoglobin (HbA). Mild anemia may occur although patients
with sickle cell trait are usually without symptoms of the disease. Under intense stressful
conditions, exhaustion, hypoxia (low oxygen), and/or severe infection may occur.

Clinical manifestations of SCD

Patients with SCD often suffer from life-threatening complications including
VOEs (acute episodes of pain), episodes of ACS, stroke/cerebral infarction or
hemorrhage, infections, splenic sequestration, anemia, renal and genitourinary issues,
avascular necrosis, cholelithiasis, and ophthalmologic complications. A study by
Loureiro et al. using records of adolescents and adults with SCD from a public teaching
hospital in Brazil found that acute episodes of pain were the most common complication
of SCD (71.7% in adolescents and 75% in adults), followed by ACS (10.4% in
adolescents and 6.5% in adults).5 Stroke is one of the highest known causes of death in
SCD patients.6 VOEs, ACS, and strokes are the most common complications in the
4

pediatric population. SCD in combination with these complications may impose a
significant burden on the patient, payers, and the society.

The burden of the above mentioned clinical manifestations of the disease will not
be realized until the epidemiology of SCD is known. The next section provides a detailed
description of the epidemiology of SCD.

Epidemiology of SCD

SCD is the most common hereditary disorder of the blood in the United States. The
Registry and Surveillance System for Hemoglobinopathies (RuSH) project is a collaborated
effort between the Centers for Disease Control and Prevention (CDC), The National Institutes of
Health (NIH), and seven states including California, Florida, Georgia, North Carolina, New
York, Michigan, and Pennsylvania to understand the epidemiology and burden of SCD.
According to their report, SCD affects a total of 90,000 to 100,000 Americans.3 The incidence
of SCD is 1 out of every 375 to 600 African-American and 1 out of every 2,000 HispanicAmerican births.7 Overall, the life expectancy for SCD patients is 42 years in men and 48 years
in women.6 A study conducted using the US Census population data reported that in 2005 there
were 89,079 people with SCD in the US of which 80,151 were African Americans and 8,928
were Hispanics.8 Another study involving analysis of the Florida Medicaid claims found that
70% of all identified SCD patients were African-American.9 The state with the highest
population of SCD patients was New York with 8,308 people, followed by Florida with 7,539
people, and Texas with 6,765 people. A more recent study conducted using the 2008 US census
data reported that national SCD population estimates ranged from 72,000 to 98,000 when
adjusted for SCD mortality in adults.10 Some variation in the prevalence of SCD was also seen
5

in terms of the phenotypes. In African-Americans, the birth prevalence of sickle cell anemia
(HbSS) is 1/375, of HbSC is 1/835, and of HbS/beta thalassemia is 1/1667.11

The next section reviews the literature pertaining to the burden associated with SCD.
Specifically, the economic burden and healthcare resource utilization associated with the disease
will be described.

Burden associated with SCD
Studies associated with disease burden of SCD provide information regarding two
parameters, namely, the economic burden and healthcare resource utilization associated with the
disease.
Economic burden of SCD
SCD imposes a significant economic burden on patients, payers, and the society.12
It is estimated that annual charges for an adult with sickle cell disease are $231,050 while
children with SCD may incur $203,813 per patient per year.13 Woods et al. analyzed a
statewide administrative dataset in Illinois (1992-1993) which consisted of 8,403 hospital
admissions for 1,189 SCD patients.14 Total hospitalization charges for these patients
were found to be more than $30 million per year. Kauf et al. analyzed Florida Medicaid
data from 2001-2005 and found that the average total cost per patient-month for SCD was
$1,946.9 For an average SCD patient surviving till the age of 45, total undiscounted
health care costs were estimated to be $953,640.
Previous studies have attempted to assess costs/charges for inpatient care
pertaining to SCD in adults. Davis et al. analyzed data from the National Hospital
6

Discharge Survey from 1989 to 1993.15 The average cost per SCD-related hospitalization
(in 1996 dollars) was estimated to be $6,300, resulting in an annual direct cost of
approximately $475 million per year. Similar costs were reported by Mayer et al. who
reported results from hospital data from the 1994 American Hospital Association (AHA)
survey.16 Nietert et al. analyzed data from the Sickle Cell Program at the Medical
University of South Carolina (MUSC) and the MUSC-affiliated Charleston Memorial
Hospital from January 1, 1996 to September 20, 1997.17 The authors found that the mean
inpatient and physician charges for an SCD-related admission were $7,290 and $1,589,
respectively. In addition, it was found that a small proportion of patients (4.2%) were
responsible for a large portion (40%) of the aggregate total charges. This indicates that
patients with severe disease incur significantly higher costs as compared to those with
less severe disease.
Emergency department (ED) visits are a significant contributor to costs in adult
patients with SCD. Lanzkron et al. analyzed the Nationwide Emergency Department
Sample (NEDS) for calendar year 2006.18 Costs for patients with SCD were compared to
those with other chronic conditions such as asthma, congestive heart failure (CHF), and
HIV. For hospitalizations associated with an ED visit, the charges per 100 SCD patients
(1.5 million) were higher than those incurred by patients with CHF ($500,000), HIV
($281,818) and asthma ($14,411). However, the mean charges per ED visit for patients
with SCD were on the lower side ($21,679) while patients with CHF, asthma, and HIV
incurred $29,317, $16,485, and $50,753 respectively. Hence, it is essential to note that
the reason for high economic burden due to ED visits in SCD patients as compared to
other conditions is the high frequency of ED visits rather than the expensive care.
7

The studies described so far report the economic burden of SCD in the adult
population. There are relatively fewer studies which assess the economic burden of SCD
in children. Although pediatric SCD patients incur lower costs as compared to adults, the
burden is still substantial.9
Mvundura et al. assessed expenditure for US children with SCD using the
Marketscan® Medicaid Database and the Marketscan® Commercial Claims and
Encounters Database for calendar year 2005.19 Interestingly, even though the percentage
of SCD children enrolled in Medicaid with an inpatient admission was higher as
compared to patients with private insurance (43% vs. 38%), mean expenditure per
admission was lower for children enrolled in Medicaid ($6,469 for Medicaid vs. $10,013
for private insurance). This may be an indication of lower reimbursements by Medicaid.
The total annual expenditure for pediatric Medicaid patients was reported to be $11,075,
while that for privately insured patients was $14,722.
Bilenker et al. compared expenditures for children with and without SCD in the
Washington State Medicaid program.20 In 1993, children with SCD had mean
expenditures 8.8 times that of the non-SCD children. Also, 10% of children with the
highest expenditures accounted for 56% of the expenditures. Out of the total
expenditures, 72% were attributed to inpatient care, followed by outpatient care (11%),
physician payments (11%), and only 3% for prescription drugs.
In an attempt to assess the national economic burden of children with SCD,
Amendah et al. analyzed the 2005 MarketScan® Medicaid and Commercial Claims
database.21 It was found that Medicaid children with SCD incurred medical expenses that
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were $9,369 higher than children without SCD. A similar trend was seen for privately
insured beneficiaries with SCD children costing $13,469 higher than those without SCD.
Healthcare resource utilization in SCD
The primary source of hospital admissions for adult patients with SCD is
emergency rooms.14 A study conducted using the Illinois Hospital Association
administrative claims data reported that SCD patients had ED as the primary source of
admission in 85.7% of the claims.14 The median number of ED admissions per SCD
patient was three, which may not be considered high since this was reported over a period
of two years. Aisiku et al. compared SCD patients who were high ED utilizers (defined
as at least 3 ED visits per year) with low utilizers.22 Only 35.5% patients with SCD were
found to be high utilizers of the ED. However, these patients were more severely ill (as
measured by laboratory variables), had more pain and distress, and had a lower quality of
life than SCD patients who were low utilizers of ED visits. Lanzkron et al. reported the
incremental burden associated with SCD as compared to other chronic conditions.18
Patients with SCD were found to have the most number of ED admissions per 100
patients (68.4) as compared to patients with asthma (1.1), HIV (5.1), and CHF (17.3).
Epstein et al. analyzed data from the SCD program at Thomas Jefferson University
Hospital.23 The 20% highest inpatient service utilizers accounted for 54% of ED visits
resulting into a hospitalization, 52% of ED visits only, 54% of hospital bed days, and
24% of office visits. The ED was a common source of health service utilization, with a
mean of 7.4 visits per patient year, a third of which resulted in a hospital admission. The
frequency of ED visits reported in this study is higher than that reported by Woods et al.14
This is probably due to the fact that this study included patients who were receiving SCD
9

care for more than three years at Thomas Jefferson University Hospital. Since this study
may be analyzing data from severely ill patients, the frequency of ED visits per patient
per month might have been higher compared to other studies.
Hospital admissions are also a common mode of healthcare resource utilization
among patients with SCD. A study by Davis et al. reported that in the US, the total
number of hospitalizations for SCD patients was 75,000 per year.15 Brousseau et al.
analyzed the 2005 and 2006 Healthcare Cost and Utilization Project (HCUP) State
Inpatient Databases and State Emergency Department Databases.24 The 21,112 patients
with SCD had an average of 1.52 encounters for hospitalizations and 1.08 for treat-andrelease ED visits per patient per year. As expected, average health service utilization was
highest for patients with public insurance (3.22 encounters per patient per year) as
compared to privately insured (1.76 encounters per patient per year) and uninsured
patients (1.42 encounters per patient per year).
Relatively fewer studies have examined SCD-related healthcare resource
utilization in children. A study using the Nationwide Emergency Department Sample
(NEDS) reported a total of 44,188 pediatric visits in 2006 due to SCD.18 Glassberg et al.
analyzed data from the Silent Cerebral Infarct Transfusion (SIT) trial which identified
children with SCD in the United States, Canada, England, and France.25 Only 0.74 ED
visits per pediatric patient per year were identified in this study. Risk factors for
increased ED visits included a history of asthma and ACS. A study by Panepinto et al.
conducted using the 1997 HCUP Kid’s Inpatient Database (KID) reported a total of total
of 20,271 hospital discharges and length of stay (LOS) of 4.4 days in SCD children with
VOEs in the US.26 Older age was associated with higher frequency of hospitalizations
10

and longer hospital stays. Leschke et al. analyzed Wisconsin Medicaid claims (20032007) and reported that the 14-day and 30-day re-hospitalization rates in children with
SCD were 10.21% and 17.2% respectively.27
The next section provides an overview of studies addressing the impact of SCD
on patient quality of life and mortality.
Quality of life and mortality in SCD
In addition to its clinical and economic impact on patients, SCD has a significant effect
on patients’ quality of life due to its long-lasting clinical manifestations. An exploratory study in
London found that SCD carries a huge psychosocial burden impacting physical, psychological,
social and occupational well-being in patients with SCD.28 In another study, McClish et al.
administered the Short Form 36 (SF-36) scale to 308 patients with SCD to determine the health
related quality of life (HRQOL) in this population.29 SCD patients scored significantly lower
than national norms on subscales including physical function, physical and emotional role
function, bodily pain, vitality, social function, and general health. When compared to asthma,
SCD patients had similar scores on physical function, role function, and mental health domains,
but lower scores for bodily pain, vitality, social function, and general health subscales.
Panepinto et al. presented child and caregiver reports of HRQOL in pediatric patients
with SCD.30 Compared with child reports, caregivers reported significantly worse HRQOL in
SCD patients in the overall perception of health, physical functioning, behavior, and self-esteem
domains (p < 0.005). High correlation in parent and child reports was found in bodily pain (r
=0.58), while domains including physical functioning (r = 0.44), behavior (r = 0.45), general
health (r = 0.44), self-esteem (r = 0.40) and changes in health (r = 0.33) were moderately
11

correlated. Also, factors including disease status, neurobehavioral co-morbidities, and parent
education were found to be predictors of HRQOL in children with SCD. Palermo et al.
compared caregiver-reported HRQOL for children with SCD with caregiver-reported HRQOL of
healthy children.31 Caregivers of children with SCD reported that their children had lower
physical, psychological, and social well-being than children without SCD.
SCD is also associated with a significant burden of mortality. A study conducted using
1995-2005 Tennessee Medicaid claims indicated that mortality rates in SCD patients are
significantly higher as compared to non-SCD African-American beneficiaries.32 A cohort study
using data from 1987 to 1996 reported that the median survival was 53 years for men and 58.5
years for women with SCD.33 The burden of mortality differs by patient demographic
characteristics. In the US, the highest rate of SCD-related mortality has been reported in
Washington D.C.2 Seizures, acute anemic episode, renal failure, VOEs, and ACS are some
predictors of mortality identified in the literature.6,34
Management of SCD has been the focus of all healthcare strategies given its substantial
burden on the diseased population. The next section describes an overview of management
strategies for SCD. Specifically, the role of sickle cell centers and treatment options in the
management of SCD will be described.
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Management of SCD

Treatment options

Timely and effective treatment is an important factor in reducing morbidity and
mortality associated with SCD. However, limited treatment options are available for
patients with SCD.

Blood transfusion and stem-cell transplants are among the most expensive options
used mainly as secondary therapies to treat patients with advanced disease.35
Transfusions result in an increase in the oxygen carrying capacity of the blood and
maximize the number of normal RBCs in circulation which helps in correcting anemia.36
Patients on blood transfusion programs have been found to have a reduced incidence of
stroke.37 Stem cell or bone marrow transplantation remains the deﬁnitive treatment for
complete cure and eradication of the disease. In patients with SCD, transplantation of
healthy bone marrow from a genetically-matched donor can lead to the production of
normal hemoglobin and an eventual reversal of the disease.38

In the late 1980s and early 1990s, researchers began investigating the potential of
hydroxyurea (HU), an anti-neoplastic agent, in reducing the frequency and severity of
crises in SCD.39,40 HU was initially approved for treating chronic myeloid leukemia,
polycythemia vera, and essential thrombocythemia. The efficacy of HU to reduce
symptoms of SCD was established in ‘The Multicenter Study of Hydroxyurea in Sickle
Cell Anemia’ trial (MSH trial) in 1995 which reported that HU reduced the annual rate of
painful events, episodes of ACS, and blood transfusions in patients with SCD.41 As a
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result, this drug was approved by the FDA in 1998 for the treatment of SCD in adults.
Although HU has not been approved for use in pediatric patients, it is recommended in
this population due to its proven safety and efficacy in reducing clinical events in
children with SCD.42–44 In a longitudinal study by Ferster et al. (2001) using the Belgian
SCD registry, HU use was associated with a significant reduction in hospitalizations in
children with SCD.45 Studies have also documented that therapy with HU results in a
decrease in the number of blood transfusions per patient.46,47

According to the guidelines published by the National Heart, Lung, and Blood
Institute (NHLBI), HU is indicated for children (after consultation with parents and
expert pediatricians) with SCD experiencing frequent pain episodes, history of acute
chest syndrome, or severe symptomatic anemia.48 Specifically, HU is indicated for use in
children who are three years of age or older; have more than two severe VOEs per year;
have more than two episodes of ACS per year; or any combination of greater than two
episodes of ACS per year and severe pain.49 The guidelines also state that no
improvement is expected until the drug has been taken daily for 3-6 months. It is
recommended that HU be initiated and monitored by hematologists since long-term HU
use may result in long-term toxicity.

Sickle cell centers

People affected by SCD require comprehensive care which involves holistic,
multi-disciplinary management of their disease. The components of comprehensive care
for patients with SCD include patient/parent/caregiver information, genetic counseling,
social services, prevention of infections, dietary advice and supplementation,
14

psychotherapy, renal and other specialist care, pain control, physiotherapy, drug
dependency services and specialist sickle cell nursing.50,51 The NIH supports 10
comprehensive sickle cell centers in the United States which carry out SCD-related
research and patient-centric activities focusing on the implementation of best models to
treat and care for patients with SCD. In addition, there are several specialized sickle cell
clinics across the US which provide care to patients with SCD. Since the goal of these
comprehensive care centers and clinics is to increase access to SCD care, they play a vital
role in improving outcomes among patients with the disease.

HU therapy in SCD

Mechanism of action of HU

Although the exact mechanism of HU in treating patients with SCD is unknown,
it is believed that HU increases the production of hemoglobin F (HbF) in RBCs.52 HbF is
the main hemoglobin in the fetus during the last seven months of uterine development
and in the newborn until roughly six months after birth. HbF prevents the polymerization
of sickle cell hemoglobin which inhibits their sickling. By increasing the production of
HbF in RBCs, it prevents the malformation of RBCs which increases the overall
proportion of normally structured RBCs in circulation thus reducing complications
associated with the disease.40 Low HbF is one of the predictors of early mortality in
patients with SCD.44 As a result, HU use not only has the potential to reduce clinical
events in SCD patients, but also to increase life expectancy.
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Utilization of HU and its impact on outcomes

Despite the MSH and other studies providing evidence for the efficacy of HU, it
is underutilized in the adult as well as the pediatric population, thus limiting its
effectiveness.53 An observational study conducted in the Florida Medicaid claims data
reported that only 38% of adult SCD patients eligible to receive HU had a prescription
claim for the same.54 The utilization of HU is even lower (approximately 8%) in children
as demonstrated by a study conducted in the South Carolina Medicaid population.55
Current research does not provide an estimate of HU use in a nationwide sample of SCD
patients. Also, it is necessary to assess predictors of HU use in the population using realworld data in order to be able to increase the utilization of HU.

The MSH was the biggest trial to date which provided evidence of the efficacy of
HU treatment in adults with SCD.41 It was reported that the median time to the first crisis
(3.0 vs. 1.5 months; p=0.01) and the second crisis (8.8 vs. 4.6 months; p<0.001) was
longer in the HU treatment group as compared to the non-treatment group. It was also
reported that fewer patients assigned to hydroxyurea had chest syndrome (25 vs. 51,
p<0.001), and fewer underwent transfusions (48 vs. 73, p=0.001). While the impact of
HU on clinical events is substantial, other studies also show that use of HU decreases
healthcare resource utilization and costs in the adult SCD population.56

While there is some evidence to suggest that HU use is associated with
improvement in SCD-related clinical outcomes among children, studies documenting
such effects are mainly clinical trials recruiting a highly restricted sample.39,42,57 There is
a scarcity of real world research demonstrating the effect of HU use in the pediatric SCD
16

population. Only one observational study has attempted to assess the association
between HU use and clinical outcomes in children using the South Carolina Medicaid
administrative claims data.58 HU users were found to have significantly more vasoocclusive crises than non-users. These results are not in accordance with the results
obtained in pediatric clinical trials demonstrating the effect of HU use on clinical
complications in SCD. Research is also lacking in terms of investigating the impact of
HU use on economic outcomes including healthcare resource utilization and costs in the
pediatric population. It is important to fill these gaps in research and provide real-world
evidence regarding the relationship between HU use and clinical and economic outcomes
in children with SCD.

The purpose of this study was to assess the prevalence of HU use in the pediatric
population with SCD and to examine the predictors of HU use in this population. In
addition, this study assessed the relationship between HU use and clinical and economic
outcomes in children with SCD. The author used the 2006-2008 Medicaid administrative
claims data for 40 US states (all US states except Hawaii, Montana, Pennsylvania, Utah,
Wisconsin, Washington DC, Wyoming, Alaska, Missouri, North Dakota, and South
Dakota) for the purpose of this study.

SCD is mainly prevalent in the African-American and Hispanic population, which
represent almost 50% of beneficiaries enrolled in Medicaid programs nationwide.59 Also,
pediatric beneficiaries contribute to a high 58% of the national Medicaid population.60
Previous research has documented that the majority of SCD patients seeking healthcare
are covered by government insurance.14,15 Given the lower than average life-span of
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those suffering from the disease, it is reasonable to assume that most of these patients are
in fact covered by Medicaid. As a result, Medicaid claims data were the appropriate
choice for obtaining a representative sample of pediatric SCD patients.

Specific aims

The specific aims of this study were:

1. To examine HU use among a cohort of children with SCD in the Medicaid population.
a. To determine the prevalence of HU use.
b. To assess demographic and health-related predictors of HU use including age,
gender, race, SCD severity, prior blood transfusions, prior office visits, prior
opioid use, and presence of a comprehensive sickle cell center in the state of
residence.
2. To investigate the association between HU use and clinical outcomes among children
with SCD in the Medicaid population.
3. To assess the relationship between HU use and healthcare resource utilization in children
with SCD in the Medicaid population.
a. To evaluate the impact of HU use on SCD-specific hospital admissions.
b. To assess the impact of HU use on length of hospital stay of SCD-specific
hospital admissions.
c. To study the impact of HU use on SCD-specific ED visits.
4. To evaluate the relationship between HU use and SCD-specific direct medical costs in
children enrolled in Medicaid.
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Significance of this study:

Current literature reporting prevalence of HU use in children with SCD using objective
real-world data is very scanty. Objective data provide real-world estimates of medication use
rather than self-reported measures which may potentially produce inflated estimates.61 Only one
study by Tripathi et al. has reported estimates for use of HU in the pediatric population using
data from South Carolina Medicaid claims.55 Although this study provided important
information regarding the prevalence of HU use among Medicaid beneficiaries in South
Carolina, the findings of this study cannot be generalized to the entire Medicaid population.

HU is the only inexpensive treatment option for patients with SCD. Despite this, more
than 60% patients who are eligible for HU based on their disease severity do not receive
treatment. In their statement on the use of HU in SCD, the NIH panel emphasized the need for
effectiveness studies identifying SCD patients that are eligible to receive HU and those who will
benefit from it.62 So far, no study has examined demographic and health-related predictors of
HU use in children with SCD. Significant predictors to HU therapy identified from this study
can help policy makers target non-users of HU so as to promote effective HU use in this
population. Also, this study may help track potential over-use of HU use in this population.
Increasing the appropriate use of HU may prove beneficial to both, the SCD patient and the
healthcare system. The goal of chapter 2 is to assess the prevalence of HU use among pediatric
Medicaid beneficiaries with SCD. In addition, demographic and health-related predictors of HU
use will be examined in this population.

Clinical complications associated with SCD, mainly vaso-occlusive crises (sickle cell
crises) bear a significant economic and psychological burden on patients and caregivers.12 The
19

association between HU use and clinical outcomes has not been explored to a great extent in the
pediatric population. Current evidence examining this relationship consists of studies which are
small clinical trials with limited generalizability.45 However, for a treatment to be considered
effective, determining its impact on clinical outcomes in a non-controlled real-world setting is
extremely crucial. Our study attempts to fill this gap by assessing the impact of HU use on
clinical outcomes in pediatric SCD patients enrolled in Medicaid programs nationwide in
Chapter 3.

In addition to studying the impact of treatment on clinical manifestations of the disease, it
is important to determine whether the treatment of SCD with HU is economical and results in a
decrease in healthcare resource utilization. This is particularly useful for health plans in making
formulary decisions. A previous study found that HU use was associated with decreased costs,
hospitalizations, and ED visits in the pediatric population.63 Although this study made a
significant contribution towards bridging a gap in research, it was conducted in the North
Carolina Medicaid population. The state of North Carolina offers specific resources related to
SCD that other states may not provide. Specifically, one of the ten NIH-endorsed
comprehensive sickle cell centers in the US is located in North Carolina. This may affect HU
use as well as clinical and economic outcomes among Medicaid beneficiaries with access to care
in these centers. As a result, the findings of this study cannot be generalized to the entire
Medicaid population. Chapter 4 assesses the relationship between HU use and healthcare
resource utilization and medical costs in the pediatric SCD population enrolled in Medicaid.
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CHAPTER 2
PAPER I
PREVALENCE AND PREDICTORS OF HYDROXYUREA USE AMONG CHILDREN
WITH SICKLE CELL DISEASE ENROLLED IN MEDICAID
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ABSTRACT
Objective: Hydroxyurea (HU) is approved for use in adult patients with sickle cell disease
(SCD) to increase the percentage of fetal hemoglobin in circulation, thus decreasing clinical
complications associated with the disease. The goal of this study was to determine the
prevalence of HU use and assess the predictors of its use in the pediatric population with SCD
enrolled in Medicaid.
Methods: The 2006-2007 Medicaid claims data from 40 US states was extracted. The inclusion
criteria for the study sample were enrollment in the Medicaid program for 18 months in calendar
years 2006-2007, age less than 18 years, and non-dual eligibility. Patients having two or more
medical claims for SCD in 2006 were identified as SCD patients. HU use among these patients
was identified using NDC codes from the prescription claims file and was defined as three or
more prescriptions of HU in a 6-month period in calendar year 2007. Prevalence of HU use was
calculated as number of HU users by the total number of patients with SCD in 2007. Age,
gender, race, SCD severity, prior blood transfusions, prior opioid prescriptions, prior office
visits, and presence of a comprehensive sickle cell center in the state of residence were tested as
predictors of HU use in SAS 9.4 using logistic regression analysis.
Results: A total of 12,213 Medicaid beneficiaries in calendar year 2006 met our inclusion
criteria. Of these, 1,309 SCD patients (10.72%) were identified as HU users in 2007. Age
(OR:1.12; 95% CI:1.11-1.14), black race (OR:0.73; 95% CI:0.65-0.83), male gender (OR:1.22;
95% CI:1.08-1.37), disease severity (OR:2.16; 95% CI:1.90-2.45), presence of a comprehensive
28

sickle cell center in the state of residence (OR:1.61; 95% CI:1.42-1.82), prior office visits
(OR:1.01; 95% CI:1.01-1.02), and having a prior opioid prescription (OR:2.07; 95% CI:1.802.39) emerged as significant predictors of HU use in this study.
Conclusion: Use of HU among children with SCD enrolled in Medicaid is very low, which
suggests that physicians exercise caution when prescribing this drug which is not approved for
use in this population. Health-related predictors that were indicators of severe disease (disease
severity, prior office visits, and prior opioid prescriptions) were found to positively affect HU
use which indicates that on average, physicians follow guidelines recommending that HU should
only be prescribed in children with severe form of the disease.
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INTRODUCTION
Sickle cell disease (SCD) is a blood disorder characterized by the presence of sickleshaped red blood cells which carry less oxygen to body tissues and can easily get lodged in small
blood vessels, thereby leading to clinical complications including stroke, acute chest syndrome
(ACS), and painful vaso-occlusive events (VOEs).1 Hydroxyurea (HU) was first approved for
adults with SCD based on clinical trials showing that HU significantly reduces VOEs, episodes
of ACS, and frequency of blood transfusions among adult patients with SCD.2–5 The efficacy of
HU in the adult as well as pediatric SCD population was later confirmed by several other
randomized trials.3,6,7 According to the guidelines published by the National Heart, Lung, and
Blood Institute (NHLBI), HU is indicated for adults and children (after consultation with parents
and expert pediatricians) with SCD experiencing frequent pain episodes, history of acute chest
syndrome, or severe symptomatic anemia.8
A 2008 Consensus Development Conference Statement by the National Institutes of
Health (NIH) identified patient-, caregiver-, provider-, and system- level barriers to HU therapy
stating that HU is underutilized among patients with SCD.9 Several studies have assessed the
utilization of HU in the adult SCD population. Lanzkron et al. used the NHLBI guidelines to
identify SCD patients eligible for HU therapy in the Maryland Health Services Cost Review
Commission database.10 The authors reported that 70% of the patients with SCD who were
eligible for HU therapy were not prescribed the medication. In their analyses of Florida
Medicaid claims data, Ritho et al. reported that only 38% of SCD adults who were eligible
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received one or more prescriptions of HU during a 5-year period (2001 to 2005).11 Another
study using data from a Maryland Medicaid managed care organization reported that only 14%
adults with SCD filled a prescription of HU from 2001 to 2005.12 Of these, 44% of the patients
filled 1–3 HU prescriptions and 29% filled 4–12 HU prescriptions, while only 27% of the
patients filled 13 or more prescriptions of HU.
Studies reporting HU use in children with SCD are relatively few in number. A selfadministered survey conducted among caregivers of children with SCD recruited from five
pediatric hematology centers in the north-east USA found that only 38% of children with SCD
were receiving HU therapy.13 An apparent limitation of this study is the use of self-report
measures for HU use which may have resulted in biased estimates.14 Tripathi et al. used 19962006 South Carolina Medicaid administrative claims to obtain an objective measure of HU use in
children. It was found that of the 2,194 children with SCD enrolled in South Carolina Medicaid,
only 175 (8.0%) received HU treatment.15 The mean duration of HU therapy was 870 days
(standard deviation [SD] = 770 days), the median being 669 days.
A few studies have assessed the prescribing patterns among providers of SCD patients
(adults as well as children). Zumberg et al. assessed the prescribing patterns of HU for SCD by
surveying hematologists in Florida and North Carolina.16 It was found that approximately 55%
of the hematologists prescribed HU in 10% of their SCD patients. Brandow et al. evaluated
prescribing patterns for HU by surveying members of the American Society of Pediatric
Hematology/Oncology.17 Of the providers that cared for SCD patients, only 9% reported that
50-90% of their SCD patients had received HU, while 10% physicians reported that less than
10% patients had received HU. The criteria used for prescribing HU were a diagnosis of ACS
and greater than two episodes of pain per year. In summary, although clinical trials have
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demonstrated that HU is effective in decreasing pain and other symptoms of SCD, its utilization
among pediatric SCD patients is low.
Research suggests that several demographic factors could affect HU use in the SCD
population. Lanzkron et al. found that that males with SCD were significantly more likely to use
HU as compared to females (22% vs. 12%, p=0.01).12 Also, HU use was found to be
significantly higher among younger as compared to older adults (mean age: 28 years vs. 32
years, p=0.02).12 It is well established in the literature that minorities receive a lower quality of
care than the White population in the US health care system, even after controlling for social
determinants and insurance status.18,19 Although not demonstrated in the SCD population,
race/ethnicity may be a potential predictor of HU use in this population.
In addition to demographic factors, health-related factors may affect HU use in patients
with SCD. According to the guidelines for HU use in the pediatric population, HU is indicated
in pediatric SCD patients (1) having more than two severe VOEs per year, OR (2) having more
than two episodes of ACS per year, OR any combination of (1) and (2) amounting to greater than
two episodes per year.20 In the previously mentioned study by Zumberg et al., it was found that
the most common reasons cited for prescribing HU in the SCD population were frequent painful
crises (76%), chronic pain with frequent narcotic use (58%), and acute chest syndrome (43%).16
This is an indication that SCD severity may be a determinant of HU use; patients with severe
disease are more likely to be prescribed HU. Blood transfusions are an alternative course of
treatment in patients with SCD which are both, time consuming and expensive. In a crosssectional study conducted among adults with SCD enrolled in Florida Medicaid, Ritho et al.
found that prior blood transfusions were a significant predictor of HU given that 73% patients in
the HU cohort had a prior blood transfusion as compared to 59% in the non-HU cohort (χ2 =
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16.3; p < 0.0001).11 Since this study was conducted in the adult population with SCD, it cannot
be said with certainty that this relationship will hold true in the pediatric population. In a survey
of parents of children suffering from SCD, Oyeku et al. reported that current HU users had
significantly greater prior physician office visits as compared to non-HU users (p<0.001).13
Contradicting this result, Candrilli et al. reported that prior physician office visits were
significantly greater in patients who were non- adherent to HU.21 Although prior office visits
represent greater access to care (which may be associated with increased medication use), they
can also be an indicator of poor health which may be associated with lower HU use. Patients
with SCD generally use opioid analgesics to curb the pain from episodes of vaso-occlusive
crises. In the previously mentioned survey by Zumberg et al. conducted in community-based
practices, frequent pain with narcotic use was one of the top reasons for physicians to prescribe
HU. Patients with prior opioid use can be expected to have a greater likelihood of HU use, as
these patients may be suffering from a more severe form of the disease. At the same time,
opioids may help in reducing pain from sickle cell crises, which may result in lower HU use
among patients using opioid analgesics. The directionality of the relationship between prior
opioid use and using HU among SCD patients remains to be examined. A well-known barrier to
HU use in children with SCD is non-compliance, which may be a result of poor access to care.17
The NIH supports 10 comprehensive sickle cell centers located across eight states in the United
States. Two centers are located in Pennsylvania and California, while Ohio, Texas, New York,
North Carolina, Massachusetts, and Tennessee have one center each. Since the purpose of these
centers is to carry out patient-centric activities focusing on the implementation of best models to
treat and care for patients with SCD, it can be expected that the use of HU is more prevalent
among patients living in these states. Although comprehensive sickle cell centers are known to
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improve outcomes, their impact on medication use among children with SCD has never been
assessed.22,23

No previous study has attempted to assess the prevalence and predictors of HU in
pediatric SCD patients nationally enrolled in Medicaid. Medicaid beneficiaries are known to
have poorer overall health, lower income, and lower access to prescription drugs compared to the
US population.24 As a result, studies conducted in other patient populations cannot be
generalized to Medicaid beneficiaries. Also, studies conducted in the adult population cannot be
extended to the pediatric population with SCD due to differences in treatment guidelines and
disease management strategies. The objectives of this study were to assess the prevalence of HU
and to identify predictors of HU use among children with SCD enrolled in Medicaid programs
nationwide.
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METHODOLOGY
Data source
Medicaid is a state-operated, federally-funded program providing healthcare coverage for
low-income individuals and families. Medicaid administrative claims data are made available
for research purposes through the Research Data Assistance Center (ResDAC), a contractor for
Centers for Medicare and Medicaid Services (CMS) that provides de-identified data in the form
of Medicaid Analytic Extract (MAX) files.
The 2006-2007 Medicaid analytic extract (MAX) files for 40 US states (all US states
except Hawaii, Montana, Pennsylvania, Utah, Wisconsin, Washington DC, Wyoming, Alaska,
Missouri, North Dakota, and South Dakota) were used for the purpose of this study. Information
regarding Medicaid enrollment, utilization, and expenditures is made available through the MAX
personal summary, inpatient claims, other services, and pharmacy claims files. The MAX
personal summary file contains person-level demographic and eligibility data for Medicaid
beneficiaries. The MAX inpatient claims file is an event level file with information regarding
the admission and discharge dates, payment amount, International Classification of Diseases,
ninth revision, clinical modification (ICD-9-CM) diagnoses codes (up to ten fields), and ICD-9CM current procedural terminology 4th edition (CPT-4) or healthcare common procedure coding
system (HCPCS) procedure codes (up to seven fields). The MAX other services file is an
outpatient facility visit-level file with information regarding physician services, clinic services,
ICD-9-CM diagnoses codes (up to two fields), and CPT-4 and HCPCS procedure codes (one
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field), provider identification number, date of service, place of service, and payment amount.
Information from outpatient (non-institutional) facilities including outpatient hospital,
physicians’ office, and emergency department is included in this file. The MAX pharmacy
claims file is a prescription-level file with information regarding National Drug Classification
(NDC) codes, days of supply for prescribed medication, quantity of drug dispensed, prescription
date, prescribing physician ID and payment amount. All the files mentioned above can be linked
by a common encrypted beneficiary ID. Approval to conduct this project was sought from the
institutional review board (IRB) at the University of Mississippi. After this, a data use
agreement (DUA) was made with CMS through ResDAC.
Patient selection
The sample for this study consisted of Medicaid enrollees from 40 US states (all US
states except Hawaii, Montana, Pennsylvania, Utah, Wisconsin, Washington DC, Wyoming,
Alaska, Missouri, North Dakota, and South Dakota) who were enrolled in the Medicaid program
for 18 months in calendar years 2006-2007 and who were less than 18 years of age. Dualeligible beneficiaries who were enrolled simultaneously in Medicaid and Medicare were
excluded from this study. The reason for their exclusion is that beneficiaries with coverage
under both the plans may have incomplete claims in the data, and certain events may not have
been reﬂected in their Medicaid claims records. Although physical impairment in patients with
SCD may begin at childhood, it is unlikely that children will qualify for Medicare due to
disability at such a young age.25 As a result, it is not anticipated that excluding dual-eligible
beneficiaries will significantly bias the results. Since HU was initially approved to treat chronic
myeloid leukemia (ICD-9-CM code 205.1), polycythemia vera (ICD-9-CM code 238.4), and
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essential thrombocythemia (ICD-9-CM code 238.71), patients with a diagnosis code for these
conditions were excluded from the study.
Calendar year 2006 served as a cohort identification period for this study. Patients
having two or more medical claims for SCD in 2006 indicated by ICD-9-CM codes in Appendix
A, Table 1 were identified as SCD patients. Among these patients, HU use was identified using
NDC codes presented in Appendix A, Table 2 from the prescription claims file.
Measures
HU use was defined as three or more prescriptions of HU in a 6-month period in calendar
year 2007. The reason for this was that the guidelines for HU use in children state that no
improvement is expected until the drug has been taken daily for 3-6 months. A measure of HU
use any less frequent than this may result in inclusion of patients with extreme under-utilization
of HU and may bias the results.
Prevalence of HU use among pediatric Medicaid beneficiaries with SCD was calculated
in calendar year 2007 as follows:

Prevalence of HU use =

Number of HU users

X 100

Total number of patients with SCD

Potential predictors of HU use including age, gender, race, SCD severity, prior blood
transfusions, prior opioid prescriptions, prior office visits, and presence of a comprehensive
sickle cell center in the state of residence were evaluated. Age was calculated as age at the end
of calendar year 2007 and was used as a continuous variable in the analysis. Gender was
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measured as a categorical variable with categories male and female. Race was used as
categorical variable. It was categorized as Black and non-Black (consisting of White, Hispanic
or Latino, Asian, Native Hawaiian or other Pacific Islander, American Indian or Alaskan Native,
or unknown race). SCD severity was measured as a binary variable in calendar year 2006.
Patients with (1) three or more severe vaso-occlusive pain events, OR (2) three or more episodes
of acute chest syndrome, OR any combination of (1) and (2) amounting to three or more
episodes were classified as having severe SCD. All others were classified as having less severe
disease. Prior blood transfusions were coded as a binary categorical variable depicting the
presence or absence of a claim for a blood transfusion in the inpatient claims and other services
files. Blood transfusions were identified using CPT-4, HCPCS procedure, and revenue codes
provided in Appendix A, Table 3. Prior office visits were calculated based on observations in
the other therapy file and were used as a continuous variable in the analysis. Observations in the
other therapy file with place of service codes 11 (office), 22 (outpatient hospital), 71 (state or
public health clinic), or 72 (rural health clinic) or procedure codes 99201-99215, 99241-99245,
99354-99355, 99381-99429 were classified as office visits. Prior opioid prescriptions were
identified using NDC codes for narcotic analgesics. The presence or absence of a
comprehensive sickle cell center in each patient’s state of residence was also represented as a
binary variable.
Statistical analyses
All statistical analyses were conducted using the Statistical Analysis System (SAS)
version 9.4 (SAS Institute Inc., Cary, NC). Means and standard deviations (SD) were reported
for count variables and frequencies and percentages were reported for categorical variables.
Bivariate analyses were conducted using t-tests for count predictors, while chi-square tests were
38

used for comparing categorical predictors between HU users and non-users. Predictors of HU
use among patients with SCD were assessed using a logistic regression model (PROC
LOGISTIC) with age, gender, race, SCD severity, prior blood transfusions, prior opioid
prescriptions, prior office visits, and presence of a comprehensive sickle cell center in the state of
residence as independent variables, and use of HU as the dependent variable.
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RESULTS
A total of 12,213 beneficiaries in calendar year 2006 met our inclusion criteria. Of these,
1,309 SCD patients (10.72%) were identified as HU users in 2007 (Appendix B, Table 1).
Results for univariable analyses between predictors and HU use conducted using t-tests
and chi square tests are presented in Appendix B, Table 2. T-tests revealed significant
relationships between age and no. of office visits, and HU use. Users of HU were significantly
older (p<0.0001), had a greater number of office visits (p<0.0001), and used a greater number of
opioid prescriptions (p<0.0001) compared to non-users. Significant relationships using chi
square tests were found between all categorical variables in the model and HU use. Non-black
race (p<0.0001), male gender (p = 0.0005), previous office visit (p<0.0036), previous blood
transfusion (p<0.0001), prior opioid visit (p<0.0001), severe disease (p<0.0001), and presence of
a comprehensive sickle cell center in the same state (p<0.0001) were all associated with
increased HU use.
The multi-variable model assessing predictors of HU use revealed interesting insights
(Appendix B, Table 3). As age increased by one year, the odds of using HU increased by 12%
(Odds ratio (OR): 1.12; 95% Confidence Interval (CI): 1.11 - 1.14). Black patients were
significantly less likely to use HU compared to patients belonging to other races (OR: 0.73; 95%
CI: 0.65 - 0.83). Males were 1.22 times more likely to use HU compared to females (95% CI:
1.08 - 1.37). Disease severity emerged as the strongest predictor of HU use. Patients with
severe disease were more likely to use HU compared to those with less severe disease (OR: 2.16;
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95% CI: 1.90 - 2.45). Patients with a comprehensive sickle cell center in the same state as their
residence were 1.61 times more likely to use HU compared to those without such a center in their
state (95% CI: 1.42 - 1.82). As prior office visits increased by one, the odds of using HU
increased by 1% (95% CI: 1.01 – 1.02). Patients who had a previous prescription for opioids had
a higher likelihood of being an HU user compared to patients who did not use opioids (OR: 2.07;
95% CI: 1.80 – 2.39).
In summary, our results indicate that utilization of HU in the pediatric population with
SCD enrolled in Medicaid is low (10.72%). Older age, non-Black race, Male gender, severe
disease, presence of a comprehensive sickle cell center in the state of residence, prior opioid use,
and prior office visits are all significant predictors of HU use in this population.
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DISCUSSION
This study assesses prevalence and predictors of HU use in the pediatric Medicaid
population with sickle cell disease. The 2006-2007 Medicaid analytic extract (MAX) files for 40
US states (all US states except Hawaii, Montana, Pennsylvania, Utah, Wisconsin, Washington
DC, Wyoming, Alaska, Missouri, North Dakota, and South Dakota) were used for this study.
Demographic and health-related predictors were evaluated.
Our study found that the prevalence of HU use among children enrolled in Medicaid in
40 US states was 10.72%. Results of previous studies reporting HU use in adults range from
30% in the Maryland Health Services Cost Review Commission database to 38% and 14% in
Florida Medicaid and Maryland Medicaid respectively.10–12 Since HU is approved for use in
adults with SCD, it is not surprising that studies conducted in this population reported
substantially more use compared to our study.
The prevalence rate for HU use found in our study is more closely aligned with previous
observational research involving pediatric patients. A 2011 study by Tripathi et al. using 19962006 South Carolina Medicaid administrative claims reported that only 8.0% children enrolled
with SCD received HU treatment.15 The only other study assessing HU use in children found
that 38% children with SCD were on HU therapy.13 However, this study included self-reported
data, which suffers from the inherent limitation of self-report bias, which may be a reason for the
reported high rates of medication use.26
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Our study found that HU use increased with age. Although ours is the first study aimed
at specifically testing predictors of HU use in the pediatric population, previous observational
studies conducted in the adult population have reported higher use of HU among younger
patients.11,12 For example, Lanzkron et al., whose analysis included five years of de-identified
data (2001–2005) from a local managed care organization (MCO), Priority Partners MCO,
serving the needs of patients on medical assistance in the State of Maryland found that that HU
use was higher among younger as compared to older adults (mean age: 28 years vs. 32 years,
p=0.02).12 Ritho et al. also reported in their study using the Florida Medicaid claims that the
mean age of HU users was lower than non-users.11 HU use has been shown to be associated with
cardiovascular, hepatic, renal, and pulmonary complications.15 A previous study conducted by
surveying members of the American Society of Pediatric Hematology/Oncology, it was found
that patient’s anticipation of side-effects and patient’s young age were two of the top five
barriers in prescribing HU among pediatric patients.17 It is not surprising that the trend seen in
our study was not similar to that seen in previous studies conducted in the adult population, as
the safety of HU in very young pediatric patients is still a major concern among prescribers and
patients. Black patients showed a lower likelihood of using HU compared to the other non-Black
races. Previous research shows that unmet prescription needs is a prevailing problem among
African-American children in the United States.27 A study conducted with a view to understand
factors that influence differences in asthma medication use among children found that AfricanAmerican children received fewer asthma medications compared to their White counterparts.28
Although our study was the first one to report that black children with SCD have a lower
likelihood of receiving HU, our results are supported by a similar trend seen in other diseases
highly prevalent in children. Our study also found that males have a higher likelihood of using
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HU compared to females. This finding is consistent with the Lanzkron et al. study conducted in
the adult SCD population (males: 22% vs. females: 12%, p=0.01).12
Health-related predictors of HU use evaluated in this study were SCD severity, prior
blood transfusions, prior office visits, prior opioid prescriptions, and presence of a
comprehensive sickle cell center in the state of residence. Disease severity emerged as a
significant predictor of HU use wherein patients with severe disease had a higher likelihood of
using HU compared to those with less-severe disease (OR: 2.65; 95% CI: 2.34 - 2.99). Although
HU is not approved for use in the pediatric population, guidelines published by the NHLBI state
that HU is indicated for children (after consultation with parents and expert pediatricians) with
SCD experiencing frequent pain episodes, history of acute chest syndrome, or severe
symptomatic anemia.8 Our study provides evidence to suggest that a majority of physicians
follow these guidelines when initiating HU treatment in pediatric patients with SCD. Prior
opioid use significantly predicted HU use in the pediatric population with SCD. Patients who
had a prior opioid prescription were significantly more likely to use HU compared to those who
did not use opioids. This finding suggests that prior opioid use is an indicator of disease
severity, and patients with greater opioid use are sicker, and in need of HU. Prior office visits
were also found to be a significant predictor of HU use in our study. Our results are in
accordance with a previous study which reported that HU users had significantly more clinic
visits during the preceding 12 months compared to non-users (p<0.0001).13 A positive
relationship between prior office visits and HU use is logical considering that greater office visits
can be an indication of disease severity, and physicians take this into account when prescribing
HU to pediatric patients with SCD.8 Patients who had a comprehensive sickle cell center within
the state of residence had a higher likelihood of using HU for their SCD compared to those who
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did not. A previous study by Shankar et al. conducted with a view to assessing the impact of
proximity of residence to a comprehensive sickle cell center on medical care utilization and
mortality failed to demonstrate a relationship between the two.22 However, presence of a
comprehensive sickle cell center within close proximity is a measure of better access to care,
which is why it is not surprising that it has a positive impact on HU use.
Our study has several strengths. First, this is an observational study conducted using
Medicaid data from 40 US states, which has the advantage of being representative of the realworld national Medicaid population with the disease. Previous studies that have attempted to do
so have used Medicaid data from a single state, the results of which cannot be generalized to the
national Medicaid population due to state-to-state differences.10–12 Second, our study is the first
of its kind to assess the prevalence and predictors of HU use in the pediatric population. A
number of previous studies with the same goal have been conducted in the adult population.10–
13,16,21

Since HU is not approved for use in the pediatric population, monitoring its use in these

patients is of utmost importance. Our study provides evidence to suggest that physicians treating
children with SCD follow guidelines that have been put in place for the effective use of HU in
this population, and prescribe it mainly to patients with severe disease.
Our study also has a fair share of limitations. First, we used at least three prescription
fills in a period of six months as a measure of HU use. However, there is no way of knowing
whether HU users continued taking the medication after those three fills, for how long they took
the medication while in the study period, and what the reasons for discontinuation were. Second,
we tested presence of a comprehensive sickle cell center within the state of residence as one of
the predictors of HU use demonstrating access to care. A better measure would be distance from
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the nearest comprehensive sickle cell center, since the nearest center for some patients could be
in an adjoining state.
In summary, the prevalence of HU use in pediatric patients enrolled in Medicaid was
found to be low. This is an indication that physicians are cautious when prescribing HU in
children, a population in which HU is not approved for use. Predictors of HU use in the pediatric
Medicaid population span from demographic variables (including age, gender, and race) to
health-related predictors (including disease severity, previous office visits, prior opioid
prescriptions, and presence of a comprehensive sickle cell center within the state of residence).
Health-related predictors that were indicators of severe disease (disease severity, prior office
visits, and prior opioid prescriptions) were found to positively affect HU use which is a testament
to the fact that on average, physicians follow guidelines from agencies such as NIH and NHLBI
recommending that HU should only be used in children with severe form of the disease. Future
research should examine the clinical and economic outcomes associated with the use of HU in
this population.
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Table 1: ICD-9-CM codes for sickle cell disease
ICD-9-CM*
code

Description

282.41

Sickle-cell thalassemia
without crisis

282.42

Sickle-cell thalassemia with
crisis

282.6

Sickle-cell disease

282.60

Sickle-cell disease,
unspecified

282.61

Hb-SS disease without crisis

282.62

Hb-SS disease with crisis

282.63

Sickle-cell/Hb-C disease
without crisis

282.64

Sickle-cell/Hb-C disease
with crisis

282.68

Other sickle-cell disease
without crisis

282.69

Other sickle-cell disease with
crisis

*ICD-9-CM: International Classification of Diseases,
9th Revision, Clinical Modification
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Table 2: NDC codes for hydroxyurea

NDC code

Trade name

Strength

0003-0830

Hydrea capsules

500 mg/1

0003-6335

Droxia capsules

200 mg/1

0003-6336

Droxia capsules

300 mg/1

0003-6337

Droxia capsules

400 mg/1

68084-284

Hydroxyurea capsules

500 mg/1

0555-0882

Hydroxyurea capsules

500 mg/1

49884-724

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

60429-265

Hydroxyurea capsules

500 mg/1

NDC = National drug classification; mg/l =milligrams per liter.
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Table 3: CPT-4, HCPCS procedure, and revenue codes for blood transfusion
Code type

Code

Description

CPT-4

36450

Exchange transfusion, blood; new born

CPT-4

36455

Exchange transfusion, blood; other than new born

CPT-4

36520

Erythrocytapheresis

CPT-4

36521

Erythrocytapheresis

CPT-4

36512

Therapeutic apheresis for red blood cells

HCPCS

P9010

Blood (whole), for transfusion, per unit

HCPCS

P9016

Red blood cells, leukocytes reduced, each unit

HCPCS

P9021

Red blood cells, each unit

HCPCS

P9022

Red blood cells, washed, each unit

HCPCS

P9038

Red blood cells, irradiated, each unit

HCPCS

P9039

Red blood cells, deglycerolized, each unit

HCPCS

P9040

Red blood cells, leukocytes reduced, irradiated, each unit

HCPCS

C1010

HCPCS

C1016

HCPCS

C1018

Whole blood or red blood cells, leukocytes reduced,
CMV-negative, each unit
Whole blood or red blood cells, leukocytes reduced,
frozen, deglycerol, washed, each unit
Whole blood, leukocytes reduced, irradiated, each unit

Revenue

380

Blood

Revenue

381

Packed red cells

Revenue

382

Whole blood

Revenue

389

Other blood

Revenue

390

Blood storage

Revenue

391

Blood administration

Revenue

399

Other blood storage and processing
th

CPT-4 = Current procedural terminology 4 edition;
HCPCS = Healthcare common procedure coding system.
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APPENDIX B – PREVALENCE AND PREDICTORS OF HYDROXYUREA
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Table 4: Prevalence of hydroxyurea use among pediatric patients with sickle cell disease
Hydroxyurea Use
Yes
No
Total

No. of patients
1,309
10,904
12,213
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% of patients
10.72%
89.28%

Table 5: Univariable analyses between predictors and hydroxyurea use
Independent variable
Age, Mean (SD)
Race
Black
Non-Black
Gender
Male
Female
Office Visit
Yes
No
No. of office visits, Mean (SD)
Disease Severity
Severe
Not severe
Prior blood transfusion/s
Yes
No
No. of prior blood transfusions,
Mean (SD)
Prior opioid prescription/s
Yes
No
No. of prior opioid prescriptions,
Mean (SD)
Comprehensive sickle cell center
in the state of residence
Yes
No

HU use

p value

Yes
9.37 (3.63)

No
6.84 (4.41)

761 (9.46)
548 (13.15)

7,285 (90.54)
3,619 (86.85)

744 (11.65)
565 (9.70)

5,643 (88.35)
5,261 (90.30)

<0.0001
<0.0001

0.0005

0.0036
1,295 (10.84)
14 (5.26)
16.52 (14.01)

10,652 (89.16)
252 (94.74)
12.04 (13.67)

666 (19.17)
643 (7.36)

2,809 (80.83)
8,095 (92.64)

381 (15.38)
928 (9.53)
0.93 (2.56)

2,097 (84.62)
8,807 (90.47)
0.92 (3.23)

<0.0001
<0.0001

<0.0001

0.8885
<0.0001

992 (15.47)
317 (5.46)
3.26 (4.26)

5,420 (84.53)
5,484 (94.54)
1.32 (2.48)

<0.0001
<0.0001

551 (13.46)
758 (9.33)

HU = Hydroxyurea; SD = Standard Deviation
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3,542 (86.54)
7,362 (90.67)

Table 6: Logistic regression analysis assessing predictors of hydroxyurea use
Independent Variable

Odds Ratio

95% Confidence Interval

1.12

1.11 - 1.14

Black
Non-black

0.73
Ref

0.65 - 0.83
-

Male
Female
Disease Severity
Yes
No
Number of Office Visits
Prior blood transfusion/s
Yes
No
Prior opioid prescription/s
Yes
No
Comprehensive sickle cell center in
the state of residence
Yes
No

1.22
Ref

1.08 - 1.37
-

2.16
Ref
1.01

1.90 - 2.45
1.01 - 1.02

1.10
Ref

0.95 - 1.26
-

2.07
Ref

1.80 - 2.39
-

1.61
Ref

1.42 - 1.82
-

Age
Race

Gender
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CHAPTER 3
PAPER II
IMPACT OF HYDROXYUREA USE ON CLINICAL OUTCOMES AMONG
CHILDREN WITH SICKLE CELL DISEASE ENROLLED IN MEDICAID
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ABSTRACT
Objectives: Hydroxyurea (HU) is the only treatment approved for use in adults with sickle cell
disease (SCD) to decrease clinical complications, mainly sickle cell crises. The goal of this
paper was to test the relationship between HU use and crises among pediatric patients with SCD
enrolled in Medicaid.
Methods: The cohort for this study comprised of HU-naïve SCD patients in 2006, who were
enrolled in the Medicaid program in 40 US states for at least 27 months from calendar year 2006
to 2008 and who were less than 18 years of age as of December 31, 2008. The relationship
between HU use and presence of a sickle cell crisis was tested using a matched cohort analysis.
HU users from the study cohort were matched with non-users on age and gender (1:1) using a
greedy matching algorithm. Presence of a sickle cell crisis in each matched pair was measured
from the date of first HU prescription to the end of 2008. The impact of HU use on number of
crises was evaluated in the unmatched sample using conventional multivariable analysis and an
instrumental variables approach, to control for observed as well as unobserved confounding. HU
users from the cohort of SCD patients described previously were identified in calendar year
2007. Number of crises for this entire unmatched sample were then identified in calendar year
2008. Regional variations in HU use at the county level and prescriber’s preference for HU were
used as instrumental variables in the analysis.
Results: The impact of HU use on presence of a sickle cell crisis in the matched cohort study
was found to be non-significant (OR: 1.33; 95% CI:0.78-2.25). Results of the conventional
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multivariable regression analysis suggested that HU users had a significantly greater number of
crises events compared to non-users (β=0.93; p<0.0001). However, upon removing the effect of
selection bias using instrumental variables, this relationship became non-significant (β=-2.75;
p=0.2013).
Conclusion: The results of our matched cohort analysis failed to corroborate the beneficial effect
of using HU in reducing the likelihood of having a crisis in children with SCD reported by
previous clinical trials. The findings from the conventional multivariable model stating that HU
use may significantly increase the number of crises in children are in accordance with previous
observational research, and this disparity between clinical trials and observational studies
indicates the presence of selection bias in observational research conducted with this goal. The
finding that use of instrumental variables steers the results in the direction of previous clinical
trials decreases the validity of previous observational studies that solely control for observed
confounding and encourages researchers to take measures to control for unobserved confounding
when assessing these relationships.
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INTRODUCTION
Approved by the US FDA (Food and Drug Administration) in 1998, hydroxyurea (HU) is
used in adult patients with sickle cell disease (SCD) to increase the percentage of fetal
hemoglobin in circulation, thus decreasing SCD-related clinical complications, mainly vasoocclusive events (VOEs).1,2 Although not approved for use in the pediatric population with
SCD, several agencies including the National Institutes of Health (NIH) recommend the use of
HU in children who have had three or more severe vaso-occlusive pain events (crises) per year,
three or more episodes of acute chest syndrome (ACS) per year, or three or more episodes of any
combination of crises and ACS events.3 The NIH published a consensus statement stating that
evidence regarding clinical outcomes of HU therapy differs in adults and children.4 In adults
with SCD, high grade evidence is available regarding the effectiveness of HU to decrease sickle
cell crises, while the evidence available in children is moderate. Two systematic reviews, one in
the adult population and another in the pediatric population with SCD also agree that current
evidence in support of HU to effectively decrease crises events is insufficient, and there is a need
of research in this area.5,6
The primary evidence for efficacy of HU as a therapeutic agent for SCD was obtained
from the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) randomized, placebocontrolled clinical trial conducted in 299 adult SCD patients at 21 sites in the United States and
Canada.7 This study found that patients assigned to the HU-treatment group had significantly
lower rates of vaso-occlusive crises than the placebo group (median: 2.5 crises vs. 4.5 crises per
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year, p < 0.001). The median times to the first crisis (3.0 months vs. 1.5 months, p = 0.01) and
the second crisis (8.8 months vs. 4.6 months, p < 0.001) were significantly longer with HU
treatment.
The safety and efficacy of HU in children was first established in a multicenter
prospective trial of HU by Scott et al. in 1996 involving 15 severely ill SCD patients.8 Several
randomized clinical trials (RCTs) ever since have established the efficacy of HU in reducing
clinical complications in children with SCD.8–13 In a pre-post study by Santos et al., frequency
of crises was measured up to one year before and after initiation of HU therapy in 21 pediatric
patients with severe SCD.10 In the period after initiation of HU, rate of crises decreased from 5
per year to 1.81 per year.
All the studies addressing the effect of HU in pediatric patients described so far are
clinical trials with limited generalizability due to enrollment of very few patients under
controlled environments. Studies conducted using a large generalizable sample and real-world
data for HU use in the pediatric SCD population will provide evidence regarding the
effectiveness of HU in this population. There are only two retrospective observational studies
reporting the impact of HU use on clinical outcomes using South Carolina Medicaid data in SCD
children. Stallworth et al. found that compared with the non-HU cohort, HU users had a
significantly higher risk of experiencing crises (Relative risk [RR] = 3.32; p < 0.0001).14
Tripathi et al. compared HU users and non-users on cerebrovascular, hepatic, renal, and
pulmonary complications while matching the two groups on a host of patient demographic and
clinical parameters. They found that the HU-treated group had a significantly higher risk of
cardiovascular (odds ratio [OR] = 3.15; confidence interval [CI] = 1.97–5.03), hepatic (OR =
5.41; CI = 3.54–8.27), renal (OR = 5.09; CI = 3.37–7.67), and pulmonary (OR = 4.07; CI =
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1.88–8.79) complications compared to the non-HU-treated group.15 The findings from these
studies are contrary to the results of previously described clinical trials regarding the effect of
HU therapy in children with SCD. A shortcoming of these studies is the inappropriate measure
of baseline disease severity, used as a confounding variable in the analyses. Disease severity
was defined as the mean number of sickle cell crises in the baseline period. This measure fails to
incorporate episodes of ACS, which is a crucial criterion in determining disease severity for
prescribing HU in the pediatric population. Another limitation of these studies is the use of data
from a single state, South Carolina, to assess the impact of HU use on clinical outcomes. As a
result, these studies lack generalizability and the aforementioned findings can only be limited to
the South Carolina Medicaid population.
Candrilli et al. analyzed North Carolina Medicaid claims data for adults and children with
SCD and found that adherence to HU therapy (medication possession ratio [MPR] ≥ 0.80) was
associated with a decrease in crises (Hazard ratio[HR]: 0.66; p = 0.013) in adults.16 However,
adherence to HU therapy was not found to be associated with VOEs among children (HR: 0.732;
p = 0.174). This may be the result of an extensively long observation period (10 years) used to
measure medication adherence which may have biased its measurement. Unlike other chronic
medications such as oral hypoglycemic agents, statins, etc., a patient may not be required to be
on HU therapy for an extended period of time because of which the calculation of medication
adherence for this condition may be difficult. Another limitation of this study was the use of
Charlson’s comorbidity index (CCI) as a measure of comorbidity which has been validated only
to predict mortality in the adult population. Applying it to pediatric patients to study outcomes
other than mortality may be inappropriate.
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Although the use of HU as a therapeutic agent in adults with SCD has been established
based on promising results from several clinical trials, evidence regarding its effectiveness in the
pediatric SCD population is mostly inconclusive. Clinical trials showing that HU use results in a
decrease in clinical complications of SCD in the pediatric population are extremely small in size
with limited generalizability. Observational studies conducted with the same goal have shown
the opposite result and have used Medicaid claims data from a single state to assess these
relationships in the pediatric SCD population. The NIH supports 10 comprehensive sickle cell
centers in the US in states including Texas, North Carolina, California (two), Ohio, NY,
Philadelphia (two), Massachusetts, and Tennessee that carry out research on improved treatments
for SCD and support activities which incorporate contemporary models of SCD care and
treatment into the clinical setting. Hence, results of studies conducted using Medicaid
administrative claims data from these states cannot be generalized to the national Medicaid
population because presence of comprehensive care centers located in specific states has been
shown to have an impact on outcomes among patients with SCD.17,18
The population with SCD enrolled in Medicaid is different from the general population.
Children with SCD enrolled in Medicaid have greater hospitalizations and ED visits as compared
to privately insured children. Despite this, mean expenditures for these events is lower among
children enrolled in Medicaid, which may indicate lower average reimbursement.19 Also,
Medicaid beneficiaries are known to have poorer overall health, lower family income, and lower
access to prescription drugs compared to the US population.20 As a result, research is needed to
assess the impact of care delivered to Medicaid-enrolled pediatric SCD patients.
An inherent general limitation of retrospective observational studies is the lack of validity
due to endogeneity: as individuals present more symptoms of SCD, the probability of receiving
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HU is likely to increase. At the same time, patients with more severe SCD are likely to have
more clinical complications. Also, prescriber characteristics may affect HU use since the
decision to prescribe HU in this population is based on the prescriber’s judgment. This is an
example of selection bias present in observational studies in which patients receiving treatment
may be inherently different from those not receiving treatment. Standard regression techniques
can only control for observed differences between the patients who receive treatment, and those
who do not by adding them as covariates in the regression model. However, they do not control
for confounding that is unobservable to the researcher. A method to minimize unobservable
confounding is by using instrumental variables (IVs) that have two properties: First, cause
variation in the treatment variable, and second, not affect the outcome measure directly. One can
then estimate how much the variation in the treatment variable that is induced by the IV affects
the outcome. This variation, known as exogenous variation, is free of endogeneity and identifies
the true relationship between the treatment and the outcome. Using methods of IV analysis to
control for the presence of selection bias leads to pseudo-randomization that stratifies patients
into different likelihoods of receiving treatment and isolates the variation of the effect of
treatment on clinical outcomes (effect of interest). This approach has been widely used in
previous research, especially in the field of econometrics.21–23
The purpose of this study was to assess the effectiveness of HU therapy on clinical
outcomes related to SCD in children enrolled in Medicaid programs from 40 US states.
Specifically, the impact of HU use on presence of sickle cell crises and the number of sickle cell
crises was tested using conventional methods of analysis. The results thus obtained were then
compared with those obtained from an instrumental variables approach designed to eliminate
selection bias, and make the results more comparable to randomized trials.
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METHODOLOGY
Data source
The 2006-2008 Medicaid analytic extract (MAX) files for 40 US states (all US states
except Hawaii, Montana, Pennsylvania, Utah, Wisconsin, Washington DC, Wyoming, Alaska,
Missouri, North Dakota, and South Dakota) were used for this study. The MAX personal
summary file contains person-level demographic and eligibility data for beneficiaries. The MAX
inpatient claims file is an event level file with information regarding the admission and discharge
dates, International Classification of Diseases, ninth revision, clinical modification (ICD-9-CM)
diagnoses codes (up to ten fields), ICD-9-CM current procedural terminology 4th edition (CPT-4)
or healthcare common procedure coding system (HCPCS) procedure codes (up to seven fields),
and payment amount. The MAX other services file is an outpatient facility visit level file with
information regarding physician services, lab/X-ray, clinic services, ICD-9-CM diagnoses codes
(up to two fields), and CPT-4 and HCPCS procedure codes (one field), provider identification
number, date of service, place of service, and payment amount. Information from outpatient
(non-institutional) facilities including outpatient hospital, physicians’ office, and emergency
department is included in this file. The MAX pharmacy claims file is a prescription level file
with information regarding National Drug Classification (NDC) code, prescription dispensed,
payment amount, days of supply, quantity dispensed, prescription date, and prescribing physician
ID. All these files mentioned above can be linked by a common encrypted beneficiary ID.
Approval to conduct this project was sought from the institutional review board (IRB) at the
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University of Mississippi. After this, a data use agreement (DUA) was made with CMS through
their Research Data Assistance Center (ResDAC).

Patient Identification and Study Design
The cohort for this study comprised of patients with SCD without a prescription of HU
(HU-naïve) in 2006, who were enrolled in the Medicaid program for at least 27 months from
calendar year 2006 to 2008 and who were less than 18 years of age as of December 31, 2008.
Dual eligible beneficiaries were excluded from the study. Also, patients having a diagnosis for
conditions including chronic myeloid leukemia (ICD-9-CM code 205.1), polycythemia vera
(ICD-9-CM code 238.4), and essential thrombocythemia (ICD-9-CM code 238.71) in the entire
study period were excluded from the study.
Calendar year 2006 served as the baseline period for identification of the SCD cohort.
Beneficiaries having two or more claims in calendar year 2006 with ICD-9-CM codes presented
in the Appendix A, Table 1 in the inpatient claims and the other services files were identified as
SCD patients. Among these, HU-naïve patients were defined as those not having a single
prescription with NDC codes from Appendix A, Table 2 in 2006. This cohort was followed into
calendar year 2007 to identify HU users and non-users.
The relationship between HU use and presence of a sickle cell crisis was tested using the
matched cohort analysis. HU users were matched with non-users on age and gender in a ratio of
1:1 using a greedy matching algorithm.24 A difference of not more than ± 2 years was allowed
while matching HU users and non-users on age, while a perfect match was requested for gender.
The date of the first HU prescription among HU users was defined as the index date and was
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attributed to each corresponding non-user. Clinical outcomes among HU users and non-users
were measured in the follow-up period from the HU index date up to December 31, 2008. A
diagrammatic representation of the matched cohort study design is provided in Appendix B,
Figure 1. The impact of HU use on number of crises was evaluated on the unmatched sample.
HU users and non-users from the cohort of SCD patients described previously were identified in
calendar year 2007. The second outcome, number of crises, was identified in calendar year 2008
(Appendix B, Figure 2).

Measures
HU users were defined as patients who had at least three prescriptions of HU in a six
month period in 2007. Sickle cell crises were measured using ICD-9-CM diagnosis codes
282.62, 282.64, and 282.69 as a primary or secondary diagnosis code in the impatient and other
services files.
Confounders including age, gender, race, baseline SCD severity, baseline office visits,
prior blood transfusions, prior opioid prescriptions, and presence (or absence) of a
comprehensive sickle cell center in the state of residence were included in the analyses. Age was
calculated as age at the end of calendar year 2008 and was used as a continuous variable in the
analysis. Gender was measured as a categorical variable with categories male and female. Race
was used as categorical variable. It was categorized as Black and Non-Black (consisting of
White, Hispanic or Latino, Asian, Native Hawaiian, Pacific Islander, American Indian or
Alaskan Native, or unknown race). Baseline SCD severity was calculated as a binary variable in
calendar year 2006. Based on SCD guidelines for pediatric patients, those with (1) three or more
severe VOEs per year, or (2) three or more episodes of ACS per year, or any combination of (1)
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and (2) amounting to three or more episodes per year were categorized as having severe disease.
All others were classified as having less severe disease. Office visits during the baseline period
were used as a proxy for access to care and past healthcare utilization. Office visits were defined
as claims in the other services file with place of service codes 11 (office), 22 (outpatient
hospital), 71 (state or public health clinic), or 72 (rural health clinic) or procedure codes 9920199213, 99241-99245, 99354-99355, 99381-99429. Prior blood transfusions was a binary
variable which denoted whether the patient underwent a blood transfusion in 2006 (using CPT-4,
HCPCS procedure, and revenue codes presented in Appendix A, Table 3. Prior opioid
prescriptions were identified using NDC codes for narcotic analgesics. An identifier variable
was created for the presence (or absence) of a comprehensive sickle cell center in the state for
patients residing in states including California, Ohio, Texas, New York, North Carolina,
Massachusetts, and Tennessee.
The instruments used in this study were measured in calendar year 2006. Three
instruments were used in this study; two instruments based on regional variations in HU use, and
one instrument denoting prescriber preference for prescription of HU. The two instruments
representing regional variations in HU use were (1) volume of Medicaid prescription claims for
HU as a percentage of the total volume of Medicaid prescriptions for SCD patients and (2)
percent volume of HU prescriptions per Medicaid beneficiary with SCD - both at the county
level.a The rationale for using these instruments is that patients would have a higher probability
of receiving HU in counties where HU diffusion was more wide-spread. Similar instruments at
the geography - level have previously been used in several studies.25–29 The third instrument

a

The instrumental variables were calculated on a sample of children as well as adults with SCD, to ensure that it is
truly exogenous and does not directly affect the outcome measure, which is calculated only in the pediatric
population.
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used in this study was prescriber’s preference for HU in the SCD population. Each SCD patient
was assigned a primary prescriber who was defined as the prescriber who wrote the maximum
number of prescriptions for that patient in calendar year 2007. Number of HU prescriptions
prescribed by the primary prescriber in 2006 as a percentage of the total prescriptions prescribed
by the prescriber during the same time period was used as the third IV in this study.
Statistical Analysis
Means and standard deviations were reported for count variables and frequencies and
percentages were reported for categorical variables. Univariable analysis using the McNemar’s
test was used to compare the categorical characteristics of the matched sample. Univariable
Poisson regressions were conducted in order to compare the distribution of count covariates in
the matched sample. Impact of HU use on presence of sickle cell crises while controlling for the
effect of covariates including race, disease severity, prior opioid prescriptions, prior blood
transfusions, prior office visits, and presence of a comprehensive sickle cell center in the state of
residence was assessed using conditional logistic regression stratified on matched pairs (PROC
LOGISTIC procedure with a STRATA statement). Univariable analysis using the chi sq. test
was conducted to compare the categorical characteristics, while t-tests were used to compare the
count characteristics of HU users and non-users in the unmatched sample. A conventional
ordinary least squares (OLS) regression using the PROC REG procedure in SAS was used to test
the impact of HU use on number of sickle cell crises, while controlling for the effects of
covariates including age, gender, race, disease severity, prior opioid prescriptions, prior blood
transfusions, prior office visits, and presence of a comprehensive sickle cell center in the state of
residence in the unmatched sample. A two stage least squares regression using the PROC
SYSLIN procedure in SAS was used to conduct the IV analysis, the estimates of which were
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then compared with the conventional multivariable model predicting the impact of HU use on
number of sickle cell crises. Statistical Analysis System (SAS) version 9.4 (SAS Institute Inc.,
Cary, NC) was used for the purposes of data management and statistical analyses in this study.
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RESULTS
A total of 238 SCD patients were identified as being HU-naïve in 2006 and were HU
users in 2007. These HU users were then matched with non-users (1:1) on age and gender. The
characteristics of this matched sample are displayed in Appendix C, Table 4. A higher
proportion of HU non-users were African-American compared to the ‘other’ race category
(p=0.0008). Compared to non-users, a higher proportion of HU users had a previous blood
transfusion (p<0.0001), prior opioid use (p<0.0001), severe disease (p<0.0001), and a
comprehensive sickle cell center located in the state of residence (p<0.0001). HU users had a
significantly higher mean number of opioid prescriptions compared to non-users (p<0.0001).
The results for the conditional logistic regression analysis between HU use and the
likelihood of having a sickle cell crisis are presented in Appendix C, Table 5. Controlling for the
effects of covariates, HU users had a higher likelihood of having a crisis event compared to nonusers (OR: 1.33; CI: 0.78-2.25). However, this relationship was not found to be statistically
significant.
The relationship between HU use and number of sickle cell crises was assessed on an
unmatched sample of 9,461 Medicaid beneficiaries with SCD, of which 235 were HU users.b
The characteristics of this sample, presented in Table 6 (Appendix C), were in general similar to
the matched study sample. HU users were significantly older compared to non-users (p<0.0001).
b

Some patients could not be assigned a primary prescriber for computation of the third IV (prescriber’s preference
for HU) as they did not have a single prescription in 2007. Also, the primary prescriber for some patients did not
write a single prescription in 2006. After excluding these patients, we were left with 9,461 patients who were used
in the analysis.
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A significantly lower proportion of HU users were black (p=0.0004), while a significantly
higherproportion of HU users had a previous blood transfusion (p<0.0001), had a previous
opioid prescription (p<0.0001), and had severe disease (p<0.0001). Also, HU users had
significantly greater number of prior blood transfusions (p<0.0001), office visits (p=0.0267), and
opioid prescriptions compared to non-users (p<0.0001).
The relationship between HU use and number of sickle cell crises was examined using a
conventional multivariable model controlling for observed confounding, and an IV model
controlling for observed as well as unobserved confounding. It is prudent to ensure that the IVs
under consideration are exogenous and explain the variation in the independent variable. As
required, all three IVs were correlated with HU use (p <0.0001) (Appendix D, Table 8).
Although the IVs did not predict variation in HU use individually (Appendix D, Table 9), they
jointly predicted variation in the treatment (F = 20.30; p<0.0001) (Appendix D, Table 10).
Lastly, the Hausman test for endogeneity was found to be significant at an alpha level of 0.1
(t=1.76; p=0.078), which provides evidence to suggest that the IVs are exogenous and the IV
model is more efficient than the conventional OLS model (Appendix D, Table 11).
A comparison of the conventional OLS model and the IV model is presented in Appendix
C, Table 7. Based on the conventional OLS model, after controlling for the effects of covariates,
HU use was found to be associated with significantly increased episodes of sickle cell crises
compared to non-users (β = 0.93; p=<0.0001). On the other hand, the IV model provided
evidence to suggest that HU users tend to have a have lower number of sickle cell crises
compared to non-users (β = -2.75). However, this relationship was not found to be statistically
significant (p = 0.2013).
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DISCUSSION
Our study, which was aimed at assessing the impact of HU use on clinical outcomes in
the pediatric population with SCD, was conducted in the Medicaid population of 40 US states.
We evaluated the impact of using HU on the likelihood of having a sickle cell crises as well as
the number of sickle cell crises.
Our study did not find a significant relationship between HU use and having a crisis
event. However, HU use was associated with a greater number of crises events compared to
non-users. Previous clinical trials conducted among pediatric patients with SCD have
demonstrated the ability of HU in reducing SCD-related events in children.8–13 However, these
studies have been conducted in a controlled setting with very few patients and fail to account for
irregularity in the use of HU. Population-based studies have an advantage over clinical trials in
that the results obtained from them are more closely aligned with real-world estimates, and
medication use in such studies is not monitored in a controlled setting.
Previous population-based observational studies conducted with the same goal have
failed to corroborate the positive clinical effects of HU use among pediatric patients with SCD.
A study conducted by Stallworth et al. using the South Carolina Medicaid claims found that
patients receiving HU experienced severe and frequent episodes of sickle cell crises over time
compared to the control group (RR: 3.32; CI: 2.49 – 4.44).14 Between 60% and 80% of all
hospitalizations for children with SCD are known to be pain-related.30 Lanzkron et al., in their
analysis of adult patients with SCD enrolled in a Medicaid managed care organization in
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Maryland found that HU users had significantly higher hospital admission rates than non-users
(5 vs. 1.5, p = .004).31 Although the estimates in the matched cohort analysis and the IV analysis
failed to reach statistical significance, our study found results in the same general direction.
In the conventional multivariable analysis testing the impact of HU use on number of
sickle cell cises, HU use was found to be significantly associated with an increased number of
crises (β = 0.93; p<0.01). Contrary to this, in the IV approach, the relationship between HU use
and number of crises was found to be negative but statistically non-significant (β = -2.75;
p=0.20). The IV approach used in our study is superior to other population-based studies aimed
at testing the beneficial effect of HU in reducing clinical outcomes in the pediatric population
with SCD. Although it failed to reach statistical significance, controlling for unobserved
confounding resulted in a change in directionality of the relationship between HU use and
number of crises. The disparity seen in previous clinical trials and population-based studies with
respect to the beneficial effect of HU use on outcomes among children with SCD may be the
result of presence of unobserved confounding, as these population-based studies fail to account
for unobserved confounding which arises due to selection bias. Further minimizing uncontrolled
confounding by the use of stronger instrumental variables may provide results in concordance
with clinical trials, thus confirming the beneficial effect HU in this population.
Our study has several strengths. Not only is it one of the very few studies assessing the
impact of HU use on clinical outcomes among pediatric patients, it is also the first observational
study with this goal to be conducted using Medicaid data from 40 US states. This large-scale
population-level study has the advantage of providing robust real-world estimates which can be
generalized to the national Medicaid population, unlike small, controlled clinical trials and
observational studies conducted using Medicaid claims from a single state. This study is also
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superior to previous population-based studies that have failed to account for unobserved
confounding that may be present in such studies comparing HU users and non-users. Results
obtained from the instrumental variables approach were found to be closer to those obtained in
previous clinical trials, and challenge the validity of previous observational studies reporting the
negative effects of HU use in pediatric patients with SCD.14,15 Our study suggests that a better
study design and robust analyses employed by observational studies in the future can potentially
establish the true effect of HU in the pediatric population in which it is not yet FDA approved.
The results of this study must be interpreted with caution. Patients who had three
prescriptions of HU within 6 months were defined as users of HU. However, we don’t know
whether all these patients continued using HU or were adherent to their medications. We tried to
overcome this by using 3 filled prescriptions of HU within a period of 6 months to define HU use
in this study. We used a period of one year (calendar year 2006) to establish HU naivity in the
cohort of SCD patients. However, we cannot be certain that the sub-cohort of HU naïve patients
thus obtained is truly HU naïve, as they may have had prescriptions of HU before 2006.
However, even if such a scenario persists, it is unlikely that any HU use before 2006 will affect
outcomes in 2007 and 2008. Even though the estimates from the instrumental variable approach
proposed in this paper are directionally consistent with results from previous clinical trials, the
method and results should be interpreted with caution. We used primary prescriber’s preference
for HU as an instrumental variable in this analysis. While we assigned the prescriber who
prescribes the most medications as a patient’s primary prescriber, there may be a scenario
wherein the primary prescriber is not an SCD expert, and the patient sees a secondary prescriber
for his SCD needs. However, this is unlikely considering that children with SCD have primary
medical needs related to the disease, and the physician treating them for SCD would most likely
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be their primary prescriber. The prescriber IDs used to identify the primary prescriber for each
patient in the sample were state-specific. This means that the prescriber’s tendency to prescribe
HU would be based solely on the patient’s state of residence. For example, if patient A’s
primary provider sees patients from a neighboring state, the prescriptions prescribed to these outof-state patients will not be counted towards the computation of the prescribing preference-based
IV for patient A.
In summary, HU use was not found to be significantly related to having a crisis event
among pediatric patients with SCD enrolled in Medicaid. A significant and positive relationship
between HU use and the number of sickle cell crises was found in the conventional multivariable
model controlling for the effects of observed confounding only. After controlling for the effect
of unobserved confounding through the use of IVs, this relationship changed directionality to
become negative, but it did not reach statistical significance. Future studies should aim at
exploring additional ways to establish the true effects of HU on clinical outcomes among
children with SCD at the population level. Effects of HU use on resource utilization and costs
associated with SCD in the pediatric population must also be investigated.
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Table 1: ICD-9-CM codes for sickle cell disease
ICD-9-CM*
code

Description

282.41

Sickle-cell thalassemia
without crisis

282.42

Sickle-cell thalassemia with
crisis

282.6

Sickle-cell disease

282.60

Sickle-cell disease,
unspecified

282.61

Hb-SS disease without crisis

282.62

Hb-SS disease with crisis

282.63

Sickle-cell/Hb-C disease
without crisis

282.64

Sickle-cell/Hb-C disease
with crisis

282.68

Other sickle-cell disease
without crisis

282.69

Other sickle-cell disease with
crisis

*ICD-9-CM: International Classification of Diseases,
9th Revision, Clinical Modification
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Table 2: NDC codes for hydroxyurea

NDC code
0003-0830

Trade name

Strength

Hydrea capsules

500 mg/1

0003-6335

Droxia capsules

200 mg/1

0003-6336

Droxia capsules

300 mg/1

0003-6337

Droxia capsules

400 mg/1

68084-284

Hydroxyurea capsules

500 mg/1

0555-0882

Hydroxyurea capsules

500 mg/1

49884-724

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

60429-265

Hydroxyurea capsules

500 mg/1

NDC = National drug classification; mg/l =milligrams per liter.
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Table 3: CPT-4, HCPCS procedure, and revenue codes for blood transfusion
Code type

Code

Description

CPT-4

36450

Exchange transfusion, blood; new born

CPT-4

36455

Exchange transfusion, blood; other than new born

CPT-4

36520

Erythrocytapheresis

CPT-4

36521

Erythrocytapheresis

CPT-4

36512

Therapeutic apheresis for red blood cells

HCPCS

P9010

Blood (whole), for transfusion, per unit

HCPCS

P9016

Red blood cells, leukocytes reduced, each unit

HCPCS

P9021

Red blood cells, each unit

HCPCS

P9022

Red blood cells, washed, each unit

HCPCS

P9038

Red blood cells, irradiated, each unit

HCPCS

P9039

Red blood cells, deglycerolized, each unit

HCPCS

P9040

Red blood cells, leukocytes reduced, irradiated, each unit

HCPCS

C1010

HCPCS

C1016

HCPCS

C1018

Whole blood or red blood cells, leukocytes reduced,
CMV-negative, each unit
Whole blood or red blood cells, leukocytes reduced,
frozen, deglycerol, washed, each unit
Whole blood, leukocytes reduced, irradiated, each unit

Revenue

380

Blood

Revenue

381

Packed red cells

Revenue

382

Whole blood

Revenue

389

Other blood

Revenue

390

Blood storage

Revenue

391

Blood administration

Revenue

399

Other blood storage and processing
th

CPT-4 = Current procedural terminology 4 edition;
HCPCS = Healthcare common procedure coding system.
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Figure 1: Matched cohort analysis to assess the impact of HU use on having a sickle cell
crisis
Identification
period for HU users
and non-users
2006

Identification of HUnaïve SCD patients
(Baseline period)*

2007

Index date (date of
first HU
prescription)

2008

Identification period
for crises for the
matched pair
(Follow-up period)

HU: Hydroxyurea
SCD: Sickle cell disease
: HU user
: HU non-user matched with the HU user
*Observed covariates were identified in the baseline period.
Note: HU users were defined as HU-naïve SCD patients (identified from calendar year 2006) having 3
prescriptions of HU within 6 months in 2007.
HU non-users were defined as HU-naïve SCD patients (identified from calendar year 2006) who do not have a
prescription of HU in 2007.
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Figure 2: Analysis using instrumental variables analyzing the relationship between HU use
and number of sickle cell crises
Identification period
for HU users and nonusers
2006

2007

Identification of HUnaïve SCD patients
(Baseline period)*

2008

Identification period
for outcomes

HU: Hydroxyurea
SCD: Sickle cell disease
*Identification of observed covariates will also take place in the baseline period.
Note: HU users were defined as HU-naïve SCD patients (identified from calendar year 2006) having 3
prescriptions of HU within 6 months in 2007.
HU non-users will be defined as HU-naïve SCD patients (identified from calendar year 2006) who do have a
prescription of HU in 2007.
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Table 4: Characteristics of the matched sample
Characteristic

HU users
(N=238)

HU non-users
(N=238)

Black
Non-black
Previous blood transfusions
Yes
No
Comprehensive center in the state
of residence
Yes
No
Previous opioid prescription
Yes
No
Disease Severity
Yes
No
No. of previous blood
transfusions, Mean (SD)
No. of previous office visits,
Mean (SD)
No. of previous opioid
prescriptions, Mean (SD)

132 (55.46)
106 (44.54)

161 (67.65)
77 (32.35)

Race

p value
0.0008

<0.0001
96 (40.34)
142 (59.66)

50 (21.01)
188 (78.99)
<0.0001

78 (32.77)
160 (67.23)

75 (31.51)
163 (68.49)

174 (73.11)
64 (26.89)

123 (51.68)
115 (48.32)

<0.0001

<0.0001
129 (54.20)
109 (45.80)
1.60 (3.27)

53 (22.27)
185 (77.73)
1.28 (4.01)

0.3606

14.20 (11.30)

12.24 (16.94)

0.1739

2.69 (3.03)

1.26 (2.01)

<0.0001

HU = Hydroxyurea; SD = Standard Deviation
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Table 5: Conditional logistic regression analysis demonstrating the relationship between
hydroxyurea use and having a sickle cell crisis event
Independent variable
HU use
Yes
No
Race
Black
Non-Black
Previous blood transfusions
Yes
No
Previous opioid prescription
Yes
No
Disease severity
Yes
No
Number of previous office visits
Comprehensive center in the state
of residence
Yes
No

Odds Ratio

Confidence Interval

1.33
Ref

0.78 - 2.25
-

0.32
Ref

0.14 - 0.73
-

1.87
Ref

0.71 - 4.93
-

1.22
Ref

0.58 - 2.57
-

2.97
Ref
1.00

1.31 - 6.77
0.96 - 1.04

0.78
Ref

0.36 - 1.70
-

HU = Hydroxyurea; Ref = Reference category
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Table 6: Characteristics of the unmatched sample for analysis using instrumental variables
Characteristic

HU users
(N=235)
8.01 (4.03)

HU non-users
(N=9,226)
6.70 (4.36)

Male
Female

127 (54.04)
108 (45.96)

4,757 (51.56)
4,469 (48.44)

Black
Non-black
Previous blood transfusions
Yes
No
Comprehensive center in the
state of residence
Yes
No
Previous opioid prescription
Yes
No
Disease Severity
Yes
No
No. of previous blood
transfusions, Mean (SD)
No. of previous office visits,
Mean (SD)
No. of previous opioid
prescriptions, Mean (SD)

130 (55.32)
105 (44.68)

6,130 (66.44)
3,096 (33.56)

93 (39.57)
142 (60.43)

1,785 (19.35)
7,441 (80.65)

Age
Gender

Race

p value
<0.0001
0.4522

0.0004

<0.0001

0.7756
78 (33.19)
157 (66.81)

2,981 (32.31)
6,245 (67.69)

172 (73.19)
63 (26.81)

4,682 (50.75)
4,544 (49.25)

<0.0001

<0.0001
127 (54.04)
108 (45.96)
1.57 (3.27)

2,339 (25.35)
6,887 (74.65)
0.99 (3.41)

0.0075

14.20 (11.36)

12.51 (14.02)

0.0267

2.63 (2.87)

1.31 (2.38)

<0.0001

HU = Hydroxyurea; SD = Standard Deviation
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Table 7: Comparison of estimates from the conventional multivariable model and the
instrumental variable model

Independent variable
HU use
Yes
No
Age
Gender
Female
Male
Race
Black
Non-black
Previous blood Transfusions
Yes
No
Comprehensive center in the
state of residence
Yes
No
Previous opioid prescription
Yes
No
Disease Severity
Yes
No
No. of previous office visits

Conventional OLS
Regression
Estimate
p value

Instrumental Variable
Analysis
Estimate
p value

0.93
Ref
0.03

<0.0001

0.11
Ref

0.0328

0.10
Ref

0.0489

-0.04
Ref

0.4467

-0.08
Ref

0.2091

0.49
Ref

<0.0001

0.57
Ref

<0.0001

0.03
Ref

0.5973

0.03
Ref

0.5494

0.66
Ref

<0.0001

0.71
Ref

<0.0001

1.45
Ref
0.01

<0.0001

1.56
Ref
0.01

<0.0001

<0.0001

0.6102

HU = Hydroxyurea; OLS = Ordinary least squares regression
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-2.75
Ref
0.03

0.2013
<0.0001

0.6810
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Table 8: Pairwise correlations between hydroxyurea use and the instrumental variables
HU use
HU use
r (p value)

1.00000

IV 1
r (p value)

0.043

IV 1

IV 2

IV 3

1.00000

(<0.0001)
IV 2
r (p value)
IV 3
r (p value)

0.040

0.895

(0.0001)

(<0.0001)

0.072

0.212

0.214

(<0.0001)

(<0.0001)

(<0.0001)
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1.00000

1.00000

Table 9: First stage regression demonstrating whether instrumental variables predict
variance in the independent variable - Test of joint significance
Source
Numerator

DF F Value p value
3

Denominator 9,449
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20.30 <.0001

Table 10: First stage regression demonstrating whether instrumental variables predict
variance in the independent variable - Test of individual significance
Variable

Parameter Estimate

t value

p value

0.001

2.64

0.008

-0.002

-0.63

0.526

-0.009

-2.69

0.007

0.028

7.24

<.0001

-0.001

-0.15

0.877

-0.000

-0.11

0.909

0.022

5.33

<.0001

0.012

3.69

0.0002

IV 1

0.002

1.24

0.217

IV 2

0.001

0.21

0.836

IV 3

0.002

6.32

<.0001

Age
Sex
Female
Male
Race
Black
Non-Black
Disease severity
Yes
No
Comprehensive sickle cell center in the
state of residence
Yes
No
Number of previous office visits
Previous blood transfusion
Yes
No
Previous opioid prescription
Yes
No
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Table 11: Hausman test for endogeneity
Variable

Estimate

t Value p value

Yes

-2.747

-1.31

0.190

0.030

4.65

<.0001

0.105

2.02

0.044

-0.075

-1.29

0.198

1.556

18.19

<.0001

0.034

0.61

0.539

0.001

0.42

0.673

0.571

6.95

<.0001

0.705

11.55

<.0001

3.701

1.76

0.078

HU use

No
Age
Sex
Female
Male
Race
Black
Non-Black
Disease severity
Yes
No
Comprehensive sickle cell center in the state of residence
Yes
No
Number of previous office visits
Previous blood transfusion
Yes
No
Previous opioid prescription
Yes
No
Residuals
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CHAPTER 4
PAPER III
HYDROXYUREA USE AND ECONOMIC OUTCOMES AMONG CHILDREN WITH
SICKLE CELL DISEASE ENROLLED IN MEDICAID
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ABSTRACT
Introduction: The objective of this study was to examine the impact of hydroxyurea (HU) on
economic outcomes in pediatric patients with sickle cell disease (SCD) enrolled in Medicaid.
The goal of this paper is to test whether the beneficial effects of using HU demonstrated in
previous clinical trials translate into decreased resource utilization and healthcare costs at the
population-level.
Methods: This was a retrospective matched cohort study conducted in a sample of HU-naïve
SCD patients in 2006 enrolled in Medicaid programs from 40 US states. The inclusion criteria
for this study was enrollment in Medicaid for at least 27 months from calendar year 2006 to
2008, age less than 18 years of age as of December 31, 2008, and non-dual eligibility. HU users
(patients with at least three fills of HU in a period of 6 months) from the study cohort were
identified in 2007 and were matched with non-users on age and gender (1:1) using a greedy
matching algorithm. The first date of HU prescription (index date) for each HU user in the
matched pair was assigned to the corresponding non-user. Economic outcomes including
presence of hospitalizations and emergency department (ED) visits, length of stay (LOS), and
medical costs in each matched pair were measured from the index date to the end of 2008.
Results: 238 HU users were matched to an equal number of non-users. HU users were
significantly more likely to have a hospitalization event (OR: 2.09; CI: 1.28 – 3.43) compared to
non-users. This group also reported a significantly longer LOS (β: 0.49; CI: 0.14 – 0.84).
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Conclusions: Healthcare providers caring for pediatric patients with SCD should weigh the
benefits and risks associated with HU use before prescribing it in this population. Most clinical
trials have reported the beneficial effects of HU use on resource utilization in children more than
one or two years after the initiation of HU therapy. Future observational studies should aim at
assessing the impact of HU use on long-term resource utilization in pediatric patients.
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INTRODUCTION
Sickle cell disease (SCD) is a chronic blood disorder affecting approximately 90,000
Americans.1 Overall, the life expectancy for patients with SCD is 42 years in men and 48 years
in women.2 In their lifetime, SCD patients may suffer from complications including painful
vaso-occlusive events (VOEs) more commonly known as sickle cell crises, episodes of acute
chest syndrome (ACS), stroke, priapism, and infections.3 SCD also significantly affects the
quality of life of patients and caregivers.4,5 As a result of its clinical and psychological
manifestations, SCD is associated with a significant economic burden.
Although not approved by the FDA in pediatric patients, research has demonstrated that
hydroxyurea (HU) can reduce crises, episodes of ACS, and stroke among other symptoms of
SCD in adults as well as in children.6–11 As a result, several agencies and organizations
including the National Institutes of Health (NIH) have recommended the use of HU in treating
children with severe SCD.
Previous studies indicate that SCD imposes a significant healthcare burden on patients.
A study by Brousseau et al. found that publicly insured adults with SCD have almost five
hospital encounters per patient per year. The re-hospitalization rates for patients with SCD were
also found to be high; 33.4% for 30-day rehospitalizations and 22.1% for 14-day
rehospitalizations.12 Another study reported that SCD patients accounted for approximately
8,400 hospital admissions and more than $59 million in hospital charges in the two-year duration
from 1992 to 1993.13 Since SCD is a condition with significant economic burden, it is important
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to demonstrate improvement in economic outcomes such as healthcare resource utilization and
costs associated with the use of HU.
Evidence from studies conducted in the adult population suggests that use of HU
significantly reduces healthcare resource utilization and costs in adults with SCD. Moore et al.
analyzed data from the Multicenter Study of Hydroxyurea (MSH) trial involving adult patients
with SCD in the United States and Canada.14 The total annual average cost per patient receiving
HU was $16,810 while that for the non-HU group was $22,020. Although this difference was
not statistically significant (p = 0.21), cost for hospitalizations due to vaso-occlusive crises was
significantly higher in the non-HU cohort as compared to the HU cohort (p = 0.048). Ferguson
et al. examined computerized medical records of 60 adults with SCD who had received HU
treatment for at least 3 months in Maryland and Washington, D.C.15 There was a significant
decline in the average number of hospitalizations per patient per year after beginning HU therapy
(0.825 hospital admissions vs. 0.52 hospital admissions per year; p = 0.04). Candrilli et al.
assessed economic outcomes of HU adherence in children and adults with SCD using the North
Carolina Medicaid claims data.16 It was found that adherence to HU therapy (medication
possession ratio [MPR] > 80%) was associated with a reduced risk of SCD-related
hospitalizations (hazard ratio [HR] = 0.65; p = 0.0351) and all-cause emergency department
(ED) visits (HR = 0.72; p = 0.0388), and a significant reduction in total healthcare costs ($6,529; p<0.0001). Adherence to HU was also associated with significant reductions in all-cause
inpatient costs, ancillary care costs, and vaso-occlusive event-related costs (p < .0001).
A few studies have assessed the impact of HU use on economic outcomes such as
healthcare resource utilization and costs in pediatric patients with SCD. The Belgian registry is a
national registry of SCD patients (children and young adults) treated with HU which was
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initiated in 1998. Ferster et al. used data from the Belgian registry to compare rate of
hospitalizations before and after initiation of HU therapy among 22 children with SCD.17
Number of hospitalizations (p = 0.0002) and length of hospital stay (p < 0.0001) were
significantly higher before initiation of HU and reduced one year after initiation of therapy. In a
more recent study using the same data, Gulbis et al. found similar results.18 Scott et al.
administered HU to 10 children with severe SCD in a multicenter, prospective trial to compare
the effect of HU use on hospitalization rate.19 At the end of one year of HU treatment it was
found that median number of hospitalizations decreased from 4.1 ± 2.2 days per month before
HU initiation to 1.0 ± 1.7 days per month after HU initiation (p = 0.03). In a sub-analysis from
the study conducted using North Carolina Medicaid claims, it was found that patients adherent to
HU had significantly lower costs for all-cause inpatient visits ($4,755 vs. $6,750; p < 0.0001),
ED visits ($204 vs. $515; p < 0.0001), and total costs ($10,140 vs. $13,658; p < 0.0001) as
compared to non-adherent patients. Costs for pharmacy services were found to be higher among
patients adherent to HU therapy ($1,246 vs. $1,041; p < 0.025); however, this is expected
considering that higher adherence will result in higher pharmacy costs.20
A drug’s effectiveness is further supported when it can produce economic savings at the
population level. Medicaid is the largest health insurer in the US providing coverage to almost
50 million people.21 Medicaid beneficiaries have poorer overall health, lower family income,
and lower access to prescription drugs compared to the US population.22 Also, children with
SCD enrolled in Medicaid have greater hospitalizations and ED visits as compared to privately
insured children.23 As a result, it is of importance to assess the relationship between HU use and
economic outcomes in this population. The previously discussed results from the Candrilli study
in children enrolled in North Carolina Medicaid cannot be generalized to the national Medicaid
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population due to presence of a comprehensive care center and differences in policy as compared
to other states. The present study aims to demonstrate the relationship between HU use and
economic outcomes in the pediatric SCD population enrolled in Medicaid programs nationwide.
The purpose of this study is to examine the impact of HU use on health services utilization
including hospitalizations, ED visits, length of hospital stay, and health care costs in pediatric
SCD patients enrolled in Medicaid programs in 40 US states.
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METHODOLOGY
Data source
The 2006-2008 Medicaid analytic extract (MAX) files for 40 US states (all US states
except Hawaii, Montana, Pennsylvania, Utah, Wisconsin, Washington DC, Wyoming, Alaska,
Missouri, North Dakota, and South Dakota) were used for the purpose of this study. Medicaid
eligibility, inpatient claims, medical claims, and pharmacy claims MAX files were used in this
study. The MAX personal summary file contains person-level demographic and eligibility data
for all Medicaid beneficiaries. The MAX inpatient claims file is an event level file containing
information regarding the admission and discharge dates, diagnoses, and payment amount. The
MAX other services file is an outpatient facility (outpatient hospital, physician office, ED) visit
level file with information regarding physician services, diagnoses, provider identification
number (ID), and payment amount. The MAX pharmacy claims file is a prescription level file
containing information regarding National Drug Classification (NDC) code, prescription
dispensed, payment amount, days of supply, quantity dispensed, prescription date, and
prescribing physician ID. All these files can be linked by a common encrypted beneficiary ID.
Approval to conduct this project was sought from the institutional review board (IRB) at the
University of Mississippi. After this, a data use agreement (DUA) was made with the CMS
through their Research Data Assistance Center (ResDAC).
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Patient identification
The cohort for this study comprised of SCD patients without a prescription of HU in
2006 (HU-naïve), who were enrolled in Medicaid for at least 18 months in calendar years 20072008, less than 18 years of age as of December 31, 2008, and who were not dual-eligibles.
Patients with conditions including chronic myeloid leukemia (International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 205.1), polycythemia vera
(ICD-9-CM code 238.4), and essential thrombocythemia (ICD-9-CM code 238.71) were
excluded from the study.
Presence of SCD was defined as having at least two medical claims for SCD (Appendix
A, Table 1) in calendar year 2006. HU-naïve patients were defined as those not having a single
HU prescription identified by NDC codes presented in Appendix A, Table 2, in 2006. This
cohort was followed into calendar years 2007 and 2008 to determine HU use and outcomes.
Measures
HU users were defined as patients who had at least three prescriptions of HU within 6
months in calendar year 2007. The date of first HU prescription was identified as the index date.
Outcomes including hospitalizations, length of hospital stay, and ED visits were measured in the
follow-up period (period after the index date) and were disease-specific. Medical costs were
identified from the personal summary file and represented all-cause costs in the form of amount
paid by Medicaid as reimbursements. Hospitalizations were defined as all events in the inpatient
file with an ICD-9-CM code for SCD (Appendix A, Table 1) as the primary or secondary
diagnosis. Length of hospital stay was calculated as number of days from the hospital admission
date to the discharge date for all patients having a hospitalization. In the event that a patient had
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multiple hospital admissions, the lengths of all the hospital stays were added to obtain a
cumulative length of hospital stay. ED visits were defined as events with place of service code
23 in the other therapy file and those with revenue codes of 450-459 or procedure codes 9928199285 in the other therapy or inpatient files with a primary or secondary diagnosis code for SCD
(Appendix A, Table 1). Since the perspective of this study was Medicaid, medical costs were
defined as amount reimbursed by Medicaid for services related to SCD (primary or secondary
diagnosis code in Appendix A, Table 1) from the inpatient and other services file.
Confounders including age, gender, race, baseline SCD severity, baseline office visits,
prior blood transfusions, prior opioid prescriptions, and presence (or absence) of a
comprehensive sickle cell center in the state of residence were included in the analyses. Age was
calculated as age at the end of calendar year 2008 and was used as a continuous variable in the
analysis. Gender was measured as a categorical variable with categories male and female. Race
was used as categorical variable and was categorized as Black and non-Black (including White,
Hispanic or Latino, Asian, Native Hawaiian, Pacific Islander, American Indian or Alaskan
Native, or unknown race). Baseline SCD severity was calculated as a binary variable in calendar
year 2006. Based on SCD guidelines for pediatric patients, those with (1) three or more severe
vaso-occlusive pain events per year, OR (2) three or more episodes of acute chest syndrome per
year, OR any combination of (1) and (2) amounting to greater than two episodes per year were
categorized as having severe disease.24 All others were classified as having less severe disease.
Baseline office visits were defined as claims in the other services file with place of service codes
11 (office), 22 (outpatient hospital), 71 (state or public health clinic), or 72 (rural health clinic) or
procedure codes 99201-99215, 99241-99245, 99354-99355, 99381-99429. Prior blood
transfusions were a binary variable which will denote whether the patient underwent a blood
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transfusion in 2006 (using CPT-4, HCPCS procedure, and revenue codes presented in Appendix
A, Table 3. Prior opioid prescriptions were identified using NDC codes for narcotic analgesics.
An identifier variable was created for the presence (or absence) of a comprehensive sickle cell
center in the state for patients residing in states including California, Ohio, Texas, New York,
North Carolina, Massachusetts, and Tennessee.
Study Design
This was a retrospective longitudinal matched cohort study. HU users identified in 2007
were matched with non-users on age and gender in a ratio of 1:1 using a greedy matching
algorithm.25 The index date for each HU user was attributed to the corresponding non-user.
Resource utilization outcomes for each pair were identified from the index date to the end of
2008.
Statistical analysis
HU use was the categorical independent variable; presence or absence of an SCD-specific
hospitalization, length of hospital stay, presence or absence of an SCD-specific ED visit, and
medical costs were dependent variables; and race, baseline SCD severity, baseline office visits,
prior blood transfusions, prior opioid prescriptions, and presence of a comprehensive sickle cell
center in the state of residence were confounding variables. Means and standard deviations were
reported for continuous variables and frequencies and percentages were reported for categorical
variables. Univariable analyses on the matched sample were conducted using McNemar’s test
for categorical variables and paired t-tests were used for count variables in order to compare the
distribution of covariates and outcomes between HU users and non-users. Categorical outcomes
including hospitalizations and ED visits were analyzed using separate conditional logistic
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regression models to determine the impact of HU use on the likelihood of having a
hospitalization and an ED visit. Multivariable analyses using conditional Poisson regressions
stratified on matched pairs were used for length of hospital stay. Since costs are not likely to be
normally distributed, the sample distribution was identified using the modified Park’s test.
Generalized linear model (GzLM) with a log link and the appropriate distribution were then used
to determine the impact of HU use on medical costs.a Data analyses were performed using
Statistical Analysis System (SAS) version 9.4 (SAS Institute Inc., Cary, NC).

a

Because we had a matched ample, costs in the GzLM were annualized so as to be comparable from one person to
another.
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RESULTS
238 patients were identified as being HU-naïve in 2006 and were HU users in 2007. To
account for the potential disparity in HU users and non-users, a sample matched on age and
gender (1:1) was created. The characteristics of this matched sample are displayed in Appendix
B, Table 4. A higher proportion of HU non-users were Black compared to HU users (p=0.0008).
Compared to non-users, a higher proportion of HU users had a previous blood transfusion
(p<0.0001), used opioids (p<0.0001), had severe disease (p<0.0001), and had a comprehensive
sickle cell center within the state of residence (p<0.0001). HU users had a significantly greater
number of opioid prescriptions compared to non-users (p<0.0001).
Univariable analysis revealed a significant inverse relationship between HU use and
hospitalizations, ED visits, and LOS (Appendix B, Table 5). A significantly greater proportion
of HU users had a hospitalization event compared to non-users (p=0.0035). Similarly, a
significantly greater proportion of HU users had an ED visit compared to non-users (p<0.0001).
The mean length of stay for HU users (17.78 days) was significantly greater than non-users (6.36
days) (p<0.0001). Also, HU users had significantly greater mean costs compared to non-users
(p<0.0001).
Multivariable analyses between HU use and outcomes representing resource utilization
including hospitalizations, ED visits, and LOS are presented in Appendix B, Tables 6, 7, and 8
respectively. Controlling for the effect of covariates, HU users were significantly more likely to
have an SCD-related hospital visit compared to non-users (OR: 2.09; CI: 1.28 – 3.43). A
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significant relationship was found between HU use and not only having a hospital visit, but also
length ofstay in the hospital. HU users had a significantly higher average LOS (β: 0.49; CI: 0.14
– 0.84) compared to non-users. The relationship between HU use and having an SCD-related
ED visit was not found to be significant (OR: 1.54; CI: 0.89 – 2.69). The results for the
multivariable model assessing the relationship between HU use and costs are presented in
Appendix B, Table 9. A Gaussian distribution was deemed appropriate for analyzing costs
through the Modified Park’s Test. The relationship between HU use and medical costs was not
significant (β: 2,228; p=0.54).
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DISCUSSION
This study assessed the impact of HU use on SCD-specific hospitalizations, ED visits,
length of stay, and medical costs in children with SCD enrolled in Medicaid in 40 US states.
This is the first study to evaluate the role of HU in health resource utilization among pediatric
patients with SCD using a national longitudinal patient-level database. This study compared
resource utilization and cost outcomes in a matched sample of HU users and non-users, thereby
providing more robust results compared to previous studies.
HU users had a higher likelihood of having a hospitalization in the follow-up period
compared to non-users. Although previous studies conducted in adults indicate otherwise,
observational studies conducted in children have found similar results stating that HU use is
associated with increase in resource use. A study by Lanzkron et al. found that in Maryland,
hospitalizations among patients with SCD have increased since the approval of HU (1.006
hospitalizations per person in 1995 to 1.288 hospitalizations per person in 2003).26 A previous
study by Tripathi et al. reported that the HU-treated group of pediatric patients was more
severely ill than the matched control group from the same SCD population.27 Despite close
matching on race, sex, age, years in data set, and baseline severity, the HU-treated group in this
study had substantially more complications than the non-HU-treated group. Apart from splenic
complications, almost all organ-specific complications were at least twice as high in the HUtreated group compared to the control group. Although we controlled for disease severity in the
multivariable model, a proxy measure (patients who had three or more crises per year, or three or
more episodes of ACS per year, or any combination of these amounting to three or more
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episodes per year were categorized as having severe disease) was used for severity, which may
not be able to completely control for confounding. Another study by Lanzkron et al. conducted
in a managed care organization in Maryland found similar results.28 Inpatient admissions for
non-users were significantly lower than those for HU users (1.5 vs. 5; p = 0.004). HU users had
an admission rate 3.9 times higher than non-users after controlling for sex, age, and outpatient
visits. Also, infrequent HU users reported greater number of admissions compared to regular
HU users. This study provides evidence to further support the hypothesis that HU users and nonusers may differ greatly in terms of SCD severity. Using a better measure of disease severity
that makes HU users and non-users more comparable is recommended for the future.
The relationship between HU use and having an ED visit was not found to be significant.
A similar relationship was also reported in the study by Candrilli et al. using North Carolina
Medicaid claims of pediatric patients.20 Previous clinical trials demonstrating the benefit of HU
use in preventing SCD-related adverse outcomes in children have been small studies with very
few participants.6,17,18 A controlled setting and smaller sample size in controlled trials limit the
extrapolation of results at a population level. The failure of our study to corroborate the benefit
of HU found in these trials raises questions regarding the effectiveness and safety of HU use in
children.
HU users were found to have a longer length of stay compared to non-users. The
Lanzkron et al. study described previously reported a mean LOS of 6.16 days in 1995 decreasing
to 5 days in 2003.26 The mean length of stay reported in our study (12.07 days) was higher than
that reported in this study. Our study was conducted using Medicaid data from 40 states.
Children enrolled in Medicaid are known to have greater number of hospitalizations (and rehospitalizations) compared to those enrolled in other insurance types.12,29 Since our length of
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stay measure is cumulative (addition of all hospitalizations in the follow-up period), it is not
surprising that the mean LOS reported in our study was higher than previously reported in
children. Also, the follow-up period in which LOS was calculated in our study was more than a
year given that HU users were identified in 2007 and LOS was calculated from the start of HU
use to the end of 2008. This may be another reason why the LOS reported in our study was
greater than Lanzkron study. Ballas et al. analyzed data from patient diaries, follow-up visit
forms, and medical contact forms on the 299 patients enrolled in the Multicenter Study of
Hydroxyurea and found no significant difference in the inpatient LOS between the HU group and
placebo (p = 0.74).30
Medical costs incurred by HU users were not found to be significantly related to HU use
after controlling for covariates. Several previous studies have reported higher costs for HU users
in the pediatric population. The study conducted among pediatric patients enrolled in South
Carolina Medicaid reported that total medical costs (emergency, outpatient, and inpatient costs)
were significantly higher for HU users compared to non-users (RR: 2.10; CI: 1.64 – 2.71).31
Emergency/inpatient costs among hydroxyurea users were significantly higher than non-users
(RR: 2.11; CI: 1.65 – 2.69). In the study by Lanzkron et al., medical costs per month for HU
users were significantly higher compared to non-users (p<0.05).28 The authors suggested that the
high costs associated with users of HU were due to the greater severity of their illness (compared
to non-users) combined with low medication adherence to HU.
By providing evidence to suggest that HU use is associated with increased likelihood of
hospitalization and a longer length of stay, our study questions the safety of HU use in the
pediatric population. Short term adverse events associated with HU use include leukopenia,
thrombocytopenia, and anemia.32 Further investigation is required to indicate whether greater
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resource use and costs associated with HU use are a result of side-effects of this medication. Our
results along with those from previous observational studies indicate that although clinical trials
have established the beneficial effect of HU in decreasing resource utilization events related to
SCD among pediatric patients, population-based studies have reported otherwise. This disparity
in research findings may be stemming from the fact that physicians tend to prescribe HU to
patients with frequent painful crises, chronic pain with frequent narcotic use, and acute chest
syndrome.33 Regular use of HU is crucial for decreasing clinical outcomes and resource
utilization. The aforementioned study by Lanzkron et al. noted that patients who had regular
refills of HU had significantly fewer inpatient visits and lower costs compared to irregular
users.28 Unfortunately, the rates of adherence to HU in the pediatric population are very low. A
study using the North Carolina Medicaid claims by Candrilli et al. reported that only 40% of the
pediatric patients were adherent to HU therapy.20 In addition, a sizable proportion of patients
prescribed HU may be non-responders (25%).34 HU being prescribed to children with more
severe form of the disease, lack of adherence to HU in this population, and the high proportion of
non-response to therapy may be collectively responsible for significantly greater resource
utilization among HU users.
Another potential reason why our results differ from those obtained in previous studies
conducted in the pediatric population is that these studies measured outcomes after a period of
continuous HU therapy.17–19 The study by Scott et al. found a significant reduction in
hospitalizations from the pre-HU period to the post-HU period only among 10 patients
completing one year of HU therapy.19 Overall, the decrease was not found to be significant
(p=0.09). This provides evidence to suggest that HU is useful in decreasing resource utilization;
however, this benefit is only realized through continuous use of HU for a long period of time.
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Due to limited data availability, we could not adopt a similar study design to test the long-term
impact of HU use on resource utilization outcomes.
Our study has several strengths. First, ours is the first study that examines the
relationship between HU use and short-term resource utilization and health care cost among
pediatric patients with SCD. Although HU is not approved for use in pediatric patients with
SCD, physicians prescribe HU in this population in cases where the disease is severe. The
results of this study can serve to inform prescribers that short-term beneficial effects of HU may
not be realized if regular use of HU is not ensured. Second, since our study uses observational
data in the form of Medicaid claims, it provides real-world population estimates for the impact of
HU use on resource utilization and cost outcomes in pediatric patients with SCD. Third, ours is
the first study conducted using Medicaid data from 40 states in the US, which has an advantage
in terms of external validity over previous observational studies, conducted within a single state.
The results from this study can be generalized to the pediatric Medicaid population with SCD.
This study also has some limitations that are worth mentioning. First, we identified
patients who had 3 fills of HU in a period of 6 months as HU users. However, there is no way to
be certain that these patients continued taking the medication after this time. Furthermore,
research suggests that up to 25% of patients might be non-responders to HU.34 Since this is an
observational study, there is no way for us to ensure that all patients classified as HU users were
responders. Continued use of HU and response to HU can affect resource utilization, both of
which were not accounted for in our study. Second, we used a period of one year (calendar year
2006) to establish HU naivity in the cohort of SCD patients. However, we cannot be certain that
the sub-cohort of HU naïve patients thus obtained is truly HU naïve, as they may have had HU
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prescriptions before 2006. However, even if such a scenario persists, it is unlikely that any HU
use before 2006 will affect outcomes in 2008.
Previous clinical trials have shown the beneficial effect of HU in decreasing SCD-related
complications among pediatric patients. Our study aimed at testing whether the potential
beneficial effect of HU translates into decreased resource utilization and healthcare costs in this
population. However, we did not find evidence to support that HU use decreases short-term
resource utilization and costs among pediatric Medicaid enrollees with SCD. In fact, our study
reported a greater risk of having an inpatient visit and longer length of stay among HU users.
Future studies should aim at understanding the reasons for increased resource utilization among
users of HU. Healthcare providers caring for pediatric patients with SCD should weigh the
benefits and risks associated with HU use before prescribing it in this population. Most clinical
trials have reported the beneficial effects of HU use on resource utilization in children more than
one or two years after the initiation of HU therapy. Future observational studies should aim at
assessing the impact of HU use on long-term resource utilization in pediatric patients.
Observational research may be subject to unobserved confounding due to vast differences in the
two treatment groups. Future studies should attempt to control for unobserved confounding
when testing the relationship between HU use and economic outcomes. If evidence for
beneficial effects of HU in the pediatric population with SCD is seen at the population level, it
has the potential for becoming a front-line treatment for children suffering from this debilitating
disease.
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Table 1: ICD-9-CM codes for sickle cell disease
ICD-9-CM*
code

Description

282.41

Sickle-cell thalassemia
without crisis

282.42

Sickle-cell thalassemia with
crisis

282.6

Sickle-cell disease

282.60

Sickle-cell disease,
unspecified

282.61

Hb-SS disease without crisis

282.62

Hb-SS disease with crisis

282.63

Sickle-cell/Hb-C disease
without crisis

282.64

Sickle-cell/Hb-C disease
with crisis

282.68

Other sickle-cell disease
without crisis

282.69

Other sickle-cell disease with
crisis

*ICD-9-CM: International Classification of Diseases,
9th Revision, Clinical Modification
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Table 2: NDC codes for hydroxyurea

NDC code

Trade name

Strength

0003-0830

Hydrea capsules

500 mg/1

0003-6335

Droxia capsules

200 mg/1

0003-6336

Droxia capsules

300 mg/1

0003-6337

Droxia capsules

400 mg/1

68084-284

Hydroxyurea capsules

500 mg/1

0555-0882

Hydroxyurea capsules

500 mg/1

49884-724

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

54868-4773

Hydroxyurea capsules

500 mg/1

60429-265

Hydroxyurea capsules

500 mg/1

NDC = National drug classification; mg/l =milligrams per liter.
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Table 3: CPT-4, HCPCS procedure, and revenue codes for blood transfusion
Code type

Code

Description

CPT-4

36450

Exchange transfusion, blood; new born

CPT-4

36455

Exchange transfusion, blood; other than new born

CPT-4

36520

Erythrocytapheresis

CPT-4

36521

Erythrocytapheresis

CPT-4

36512

Therapeutic apheresis for red blood cells

HCPCS

P9010

Blood (whole), for transfusion, per unit

HCPCS

P9016

Red blood cells, leukocytes reduced, each unit

HCPCS

P9021

Red blood cells, each unit

HCPCS

P9022

Red blood cells, washed, each unit

HCPCS

P9038

Red blood cells, irradiated, each unit

HCPCS

P9039

Red blood cells, deglycerolized, each unit

HCPCS

P9040

Red blood cells, leukocytes reduced, irradiated, each unit

HCPCS

C1010

HCPCS

C1016

HCPCS

C1018

Whole blood or red blood cells, leukocytes reduced,
CMV-negative, each unit
Whole blood or red blood cells, leukocytes reduced,
frozen, deglycerol, washed, each unit
Whole blood, leukocytes reduced, irradiated, each unit

Revenue

380

Blood

Revenue

381

Packed red cells

Revenue

382

Whole blood

Revenue

389

Other blood

Revenue

390

Blood storage

Revenue

391

Blood administration

Revenue

399

Other blood storage and processing
th

CPT-4 = Current procedural terminology 4 edition;
HCPCS = Healthcare common procedure coding system.
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Table 4: Characteristics of the matched sample
Variable

HU users
(N=238)

HU non-users
(N=238)

Black
Non-black
Blood transfusion
Yes
No
Comprehensive sickle
cell center
Yes
No
Opioid use
Yes
No
Disease Severity
Yes
No
No. of blood
transfusions
No. of office visits,
Mean (SD)
No. of opioid
prescriptions

132 (55.46)
106 (44.54)

161 (67.65)
77 (32.35)

Race

p value
0.0008

<0.0001
96 (40.34)
142 (59.66)

50 (21.01)
188 (78.99)
<0.0001

78 (32.77)
160 (67.23)

75 (31.51)
163 (68.49)

174 (73.11)
64 (26.89)

123 (51.68)
115 (48.32)

<0.0001

<0.0001
129 (54.20)
109 (45.80)
1.60 (3.27)

53 (22.27)
185 (77.73)
1.28 (4.01)

0.3606

14.20 (11.30)

12.24 (16.94)

0.1739

2.69 (3.03)

1.26 (2.01)

<0.0001

HU = Hydroxyurea; SD = Standard Deviation

.
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Table 5: Univariable analyses demonstrating relationships between hydroxyurea use and
outcomes in the matched sample
Variable
Hospitalization, N (%)
Yes
No
ED visit, N (%)
Yes
No
Length of stay, Mean
(SD)
Medical Costs, Mean
(SD)

HU user
(N = 238)

HU non-users
(N = 238)

164 (68.91)
74 (31.09)

114 (47.90)
124 (52.10)

P value
0.0035

<0.0001
182 (76.47)
56 (23.53)
17.78 (23.95)

143 (60.08)
95 (39.92)
6.36 (16.10)

<0.0001

31,847.16 (36,516.36)

19,237.07 (44,820.67)

<0.0001

HU = Hydroxyurea; SD = Standard Deviation
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Table 6: Conditional logistic regression analysis assessing the relationship between
hydroxyurea use and having a hospitalization event
Independent variable
Hydroxyurea use
Yes
No
Race
Black
Non-Black
Previous blood transfusion
Yes
No
Comprehensive center in the
state of residence
Yes
No
Previous opioid prescription
Yes
No
Disease severity
Yes
No
Number of office visits

Odds Ratio

Confidence Interval

2.09

1.28 - 3.43

0.82

0.38 - 1.80

1.90

0.84 - 4.32

1.24

0.60 - 2.57

0.74

0.35 - 1.56

2.05

1.01 - 4.17

1.01

0.99 - 1.03
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Table 7: Conditional logistic regression analysis evaluating the relationship between
hydroxyurea use and having an emergency department visit
Independent variable
Hydroxyurea use
Yes
No
Race
Black
Non-Black
Previous blood transfusion
Yes
No
Comprehensive center in the
state of residence
Yes
No
Previous opioid prescription
Yes
No
Disease severity
Yes
No
Number of office visits

Odds Ratio

Confidence Interval

1.54

0.89 - 2.69

1.30

0.59 - 2.86

2.69

0.99 - 7.27

1.56

0.72 - 3.38

1.02

0.45 - 2.31

3.04

1.43 - 6.48

0.99

1.00 - 1.03
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Table 8: Poisson regression assessing the relationship between hydroxyurea use and length
of stay
Independent variable
Hydroxyurea use
Yes
No
Race
Black
Non-Black
Previous blood transfusion
Yes
No
Comprehensive center in the
state of residence
Yes
No
Previous opioid prescription
Yes
No
Disease severity
Yes
No
Number of office visits

Parameter Estimate

Confidence Interval

0.49

0.14 - 0.84

-0.24

-0.55 - 0.08

0.51

0.24 - 0.78

0.36

0.03 - 0.58

0.10

-0.05 - 0.77

1.00

0.67 - 1.33

0.01

-0.01 - 0.01

136

Table 9: Generalized linear model predicting the effect of hydroxyurea use on costs
Independent variable
Hydroxyurea use
Yes
No
Race
Black
Non-Black
Previous blood transfusion
Yes
No
Comprehensive center in the
state of residence
Yes
No
Previous opioid prescription
Yes
No
Disease severity
Yes
No
Number of office visits

Parameter Estimate

p value

2,228.12

0.54

-4978.64

0.16

22,114.29

<0.01

9,849.34

<0.01

236.25

0.95

13,927.47

<0.01

473.27

<0.01
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DISCUSSION
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The goal of this chapter is to conclude this dissertation with a general discussion. First,
key findings will be summarized, followed by implications of this research. This chapter will
conclude with overall strengths and limitations of this dissertation, directions for future research
and a brief conclusion.
Summary of key findings
This dissertation sought to report the prevalence and predictors of use of hydroxyurea
(HU), and its impact on clinical outcomes, resource utilization, and costs in pediatric Medicaid
beneficiaries with sickle cell disease (SCD) enrolled in 40 US states. The prevalence of HU use
in this population was found to be 10.72%. Predictors of HU use spanned from demographic
variables, including age, gender, and race to health-related predictors, including disease severity,
prior opioid prescriptions, previous office visits, and presence of a comprehensive sickle cell
center within the state of residence. Although HU use did not have a significant impact on
likelihood of having a sickle cell crisis, HU users were found have a significantly higher number
of crises compared to non-users after controlling for the effects of observed covariates in a
conventional multivariable model. After controlling for the effects of unobserved confounding
through the use of instrumental variables (IVs), the relationship between HU use and number of
sickle cell crises became negative, but was statistically insignificant. Lastly, HU users had a
significantly higher likelihood of having a hospitalization compared to non-users. The length of
stay was also found to be significantly longer among HU users.
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Implications of the study
The results reported in this dissertation have implications for researchers and healthcare
providers treating children with SCD. This study reported that the utilization of HU in the
pediatric Medicaid population with SCD is only 10.72%. Given that HU is not approved by the
US Food and Drug Administration (FDA) for use in the pediatric population, and there is
uncertainty regarding its safety and effectiveness in treating SCD-related complications in this
population, our study provides evidence to suggest that providers are exercising caution when
prescribing this drug in this population. Also, the finding that health-related predictors that are
indicators of severe disease (SCD severity, prior office visits, and prior opioid use) positively
predicted the prescription of HU supports the fact that physicians treating these patients with
SCD follow guidelines that have been put in place for effective use of HU in this population.1
Unlike previous clinical trials, this study did not find evidence to support that HU use decreases
clinical complications and resource utilization in the pediatric SCD population.2–9 This finding
calls for caution among health-care providers using HU to treat SCD-related complications in
children. This dissertation points to the fact that although clinical trials are required for drug
approval and labeling purposes, they are conducted in a controlled setting, and the results
obtained in these trials may not be supported by population-based studies. The decision to
prescribe a particular drug in a segment of the population in which it is not approved should be
based on treatment guidelines and research conducted in the form of clinical trials as well as
population-based studies.
Our study found a difference in the results obtained through conventional multivariable
regression controlling for observed confounders and IV analysis that can control for observed as
well as unobserved confounding when assessing the relationship between HU use and number of
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sickle cell crises. Unobserved confounding exists when the two groups being compared (HU
users and non-users) are inherently different. Not only should results of previous observational
studies assessing the impact of HU use on clinical outcomes and resource utilization be
interpreted with caution, researchers conducting such studies in the future should account for
unobserved confounding so as to make the results more robust and valid.
Strengths and limitations of the study
This is the first study to report the prevalence and predictors of HU in pediatric patients
with SCD using nationwide Medicaid claims data from 40 US states. Since HU is not approved
by the US FDA for use in this population, it is important to ensure that this drug is being utilized
appropriately. Ours is the first study to shed some light on characteristics that determine the
prescription of HU in pediatric patients with SCD, and may assist in the decision-making process
for prescribers treating such patients.
Using insurance claims data for evaluating outcomes associated with medication use has
several advantages over clinical trials conducted to test drug efficacy. Claims data represent
real-world medication use, and are thus capable of providing real-world population-based
estimates as opposed to clinical trials in which medication use is controlled in a small sample of
participating patients. This dissertation, which used Medicaid claims data from 40 US states has
a definite advantage in its generalizability.
This is the first large-scale observational study with a view to assess the prevalence and
predictors of HU use and its impact on clinical and resource utilization outcomes in the pediatric
population with SCD conducted using Medicaid claims data from 40 US states. SCD is mainly
prevalent in the African-American and Hispanic population, representing almost 50% of
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beneficiaries enrolled in Medicaid programs nationwide.10 Also, pediatric beneficiaries
contribute to a high 58% of the national Medicaid population.11 Previous research has
documented that the majority of SCD patients seeking healthcare are covered by government
insurance.12,13 Given the lower than average life-span of those suffering from the disease, it is
reasonable to assume that most of the pediatric patients with SCD are covered by Medicaid.
Thus, our study has the advantage of being more generalizable to the SCD population in the US
compared to the retrospective observational studies conducted previously with a similar goal.14–16
This study uses robust methods of analyses to compare sickle cell crises, resource
utilization, and costs among HU users and non-users. All analyses comparing the presence or
absence of outcomes included a sample of HU users and non-users matched on age and gender.
An additional outcome, number of sickle cell crises, was compared between HU users and nonusers using a conventional multivariable model controlling for the effect of observed
confounding as well as an IV approach additionally controlling for the effect of unobserved
confounding. Standard regression techniques can only control for observed differences between
the patients who receive treatment, and those who do not by adding them as covariates in the
regression model. However, they do not control for confounding that is unobservable to the
researcher, which stems from selection bias prevalent in observational research because of
patients in the two treatment groups being inherently different from one another. This study has
a clear methodological advantage over other observational studies conducted using conventional
multivariable approaches only.
Medical and prescription claims data may suffer from coding errors during claims
processing. For example, the primary and secondary ICD-9-CM code for a patient visiting a
physician’s office for a sickle cell crisis may be incorrectly coded as the ICD-9-CM code for
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sickle cell disease. Since we used ICD-9-CM codes to identify outcomes in this study, there is a
possibility that some outcomes may be incorrectly identified. However, an assumption can be
made that these errors are distributed evenly in both, the treatment and untreated groups, thus
nullifying their effect on the outcomes.
Another disadvantage of using secondary claims data is that proxies have to be used
when measuring certain parameters. For example, we used at least three prescription fills in a
period of six months as a measure of HU use. However, there is no way of knowing whether HU
users continued taking HU after those three fills, for how long they took HU while in the study
period, what were the reasons for discontinuation of HU, etc. There was also no way of knowing
whether patients identified as HU users were on an HU prescription during the time of
measurement of the outcome.
Directions for future research
This study evaluated demographic and health-related predictors for HU use in children
with SCD. Since HU is not approved by the US FDA for use in SCD children, there may be
some physician-related factors such as specialty, practice patterns, location, etc. that may
influence the use of HU in this population. Future studies should explore these physician-related
predictors to gain more insight into the utilization patterns of HU in this population.
Our study was unable to corroborate the beneficial effect of HU on clinical outcomes in
children with SCD that was apparent in previous clinical trials. We tried to control for
unobserved confounding by the use of IVs, but there may still be some amount of unobserved
confounding that our study did not account for. Future researchers should explore the use of

143

novel IVs or use other methods while testing relationships between HU use and clinical
outcomes and resource utilization in the pediatric population with SCD.
In conclusion, this study is the first of its kind to report the prevalence and predictors of
HU treatment in children with SCD enrolled in the Medicaid programs in 40 US states. The
prevalence of HU use in this population was found to be low, and was associated with certain
demographic and health-related factors. Our study was unable to establish the beneficial effect
of HU on clinical outcomes and resource utilization, thus warranting the need for more
observational real-world studies with robust methodologies in this population.
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